TY  - JOUR
AU  - Tomić Vujović, Kristina
AU  - Ugrin, Milena
AU  - Tošić, Nataša
AU  - Vuković, Vojin
AU  - Marjanović, Irena
AU  - Kostić, Tatjana
AU  - Stanković, Sanja
AU  - Otasević, Vladimir
AU  - Sarać, Sofija
AU  - Antić, Darko
AU  - Pavlović, Sonja
AU  - Karan-Đurasević, Teodora
PY  - 2024
UR  - https://www.mdpi.com/1422-0067/25/2/922
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2318
AB  - Dysregulated expression of the long non-coding RNA MALAT1 has been implicated in the pathogenesis and progression of a variety of cancers, including hematological malignancies, but it has been poorly investigated in chronic lymphocytic leukemia (CLL). In this study, the expression of MALAT1 was measured using a quantitative reverse-transcriptase polymerase chain reaction in the peripheral blood mononuclear cells of 114 unselected, newly diagnosed CLL patients in order to analyze its association with clinical, laboratory, and molecular patients’ characteristics at diagnosis, as well as its prognostic relevance. MALAT1 was found to be upregulated in CLL patients in comparison to healthy controls, and expression levels were not related to age, leukocyte, lymphocyte and platelet count, serum β2-microglobulin, and IGHV somatic hypermutational status. On the other hand, high MALAT1 expression was associated with several favorable prognostic markers (high hemoglobin, low serum lactate dehydrogenase, earlier clinical stages, CD38-negative status), but also with unfavorable cytogenetics. Furthermore, an association between high MALAT1 levels and longer time to first treatment and overall survival in IGHV-unmutated CLL subtype was observed. In summary, our results imply that high MALAT1 expression at diagnosis may be a predictor of better prognosis and point to MALAT1 expression profiling as a candidate biomarker potentially useful in clinical practice.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia
IS  - 2
SP  - 922
VL  - 25
DO  - 10.3390/ijms25020922
ER  - 

@article{
author = "Tomić Vujović, Kristina and Ugrin, Milena and Tošić, Nataša and Vuković, Vojin and Marjanović, Irena and Kostić, Tatjana and Stanković, Sanja and Otasević, Vladimir and Sarać, Sofija and Antić, Darko and Pavlović, Sonja and Karan-Đurasević, Teodora",
year = "2024",
abstract = "Dysregulated expression of the long non-coding RNA MALAT1 has been implicated in the pathogenesis and progression of a variety of cancers, including hematological malignancies, but it has been poorly investigated in chronic lymphocytic leukemia (CLL). In this study, the expression of MALAT1 was measured using a quantitative reverse-transcriptase polymerase chain reaction in the peripheral blood mononuclear cells of 114 unselected, newly diagnosed CLL patients in order to analyze its association with clinical, laboratory, and molecular patients’ characteristics at diagnosis, as well as its prognostic relevance. MALAT1 was found to be upregulated in CLL patients in comparison to healthy controls, and expression levels were not related to age, leukocyte, lymphocyte and platelet count, serum β2-microglobulin, and IGHV somatic hypermutational status. On the other hand, high MALAT1 expression was associated with several favorable prognostic markers (high hemoglobin, low serum lactate dehydrogenase, earlier clinical stages, CD38-negative status), but also with unfavorable cytogenetics. Furthermore, an association between high MALAT1 levels and longer time to first treatment and overall survival in IGHV-unmutated CLL subtype was observed. In summary, our results imply that high MALAT1 expression at diagnosis may be a predictor of better prognosis and point to MALAT1 expression profiling as a candidate biomarker potentially useful in clinical practice.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia",
number = "2",
pages = "922",
volume = "25",
doi = "10.3390/ijms25020922"
}

Tomić Vujović, K., Ugrin, M., Tošić, N., Vuković, V., Marjanović, I., Kostić, T., Stanković, S., Otasević, V., Sarać, S., Antić, D., Pavlović, S.,& Karan-Đurasević, T.. (2024). Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia. in International Journal of Molecular Sciences
MDPI., 25(2), 922.
https://doi.org/10.3390/ijms25020922

Tomić Vujović K, Ugrin M, Tošić N, Vuković V, Marjanović I, Kostić T, Stanković S, Otasević V, Sarać S, Antić D, Pavlović S, Karan-Đurasević T. Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia. in International Journal of Molecular Sciences. 2024;25(2):922.
doi:10.3390/ijms25020922 .

Tomić Vujović, Kristina, Ugrin, Milena, Tošić, Nataša, Vuković, Vojin, Marjanović, Irena, Kostić, Tatjana, Stanković, Sanja, Otasević, Vladimir, Sarać, Sofija, Antić, Darko, Pavlović, Sonja, Karan-Đurasević, Teodora, "Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia" in International Journal of Molecular Sciences, 25, no. 2 (2024):922,
https://doi.org/10.3390/ijms25020922 . .

TY  - JOUR
AU  - Tomić Vujović, Kristina
AU  - Ugrin, Milena
AU  - Tošić, Nataša
AU  - Vuković, Vojin
AU  - Marjanović, Irena
AU  - Kostić, Tatjana
AU  - Stanković, Sanja
AU  - Otašević, Vladimir
AU  - Šarac, Sofija
AU  - Antić, Darko
AU  - Pavlović, Sonja
AU  - Karan-Đurašević, Teodora
PY  - 2024
UR  - https://www.mdpi.com/1422-0067/25/2/922
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2310
AB  - Dysregulated expression of the long non-coding RNA MALAT1 has been implicated in the pathogenesis and progression of a variety of cancers, including hematological malignancies, but it has been poorly investigated in chronic lymphocytic leukemia (CLL). In this study, the expression of MALAT1 was measured using a quantitative reverse-transcriptase polymerase chain reaction in the peripheral blood mononuclear cells of 114 unselected, newly diagnosed CLL patients in order to analyze its association with clinical, laboratory, and molecular patients’ characteristics at diagnosis, as well as its prognostic relevance. MALAT1 was found to be upregulated in CLL patients in comparison to healthy controls, and expression levels were not related to age, leukocyte, lymphocyte and platelet count, serum β2-microglobulin, and IGHV somatic hypermutational status. On the other hand, high MALAT1 expression was associated with several favorable prognostic markers (high hemoglobin, low serum lactate dehydrogenase, earlier clinical stages, CD38-negative status), but also with unfavorable cytogenetics. Furthermore, an association between high MALAT1 levels and longer time to first treatment and overall survival in IGHV-unmutated CLL subtype was observed. In summary, our results imply that high MALAT1 expression at diagnosis may be a predictor of better prognosis and point to MALAT1 expression profiling as a candidate biomarker potentially useful in clinical practice.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T2  - International Journal of Molecular Sciences
T1  - Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia
IS  - 2
SP  - 922
VL  - 25
DO  - 10.3390/ijms25020922
ER  - 

@article{
author = "Tomić Vujović, Kristina and Ugrin, Milena and Tošić, Nataša and Vuković, Vojin and Marjanović, Irena and Kostić, Tatjana and Stanković, Sanja and Otašević, Vladimir and Šarac, Sofija and Antić, Darko and Pavlović, Sonja and Karan-Đurašević, Teodora",
year = "2024",
abstract = "Dysregulated expression of the long non-coding RNA MALAT1 has been implicated in the pathogenesis and progression of a variety of cancers, including hematological malignancies, but it has been poorly investigated in chronic lymphocytic leukemia (CLL). In this study, the expression of MALAT1 was measured using a quantitative reverse-transcriptase polymerase chain reaction in the peripheral blood mononuclear cells of 114 unselected, newly diagnosed CLL patients in order to analyze its association with clinical, laboratory, and molecular patients’ characteristics at diagnosis, as well as its prognostic relevance. MALAT1 was found to be upregulated in CLL patients in comparison to healthy controls, and expression levels were not related to age, leukocyte, lymphocyte and platelet count, serum β2-microglobulin, and IGHV somatic hypermutational status. On the other hand, high MALAT1 expression was associated with several favorable prognostic markers (high hemoglobin, low serum lactate dehydrogenase, earlier clinical stages, CD38-negative status), but also with unfavorable cytogenetics. Furthermore, an association between high MALAT1 levels and longer time to first treatment and overall survival in IGHV-unmutated CLL subtype was observed. In summary, our results imply that high MALAT1 expression at diagnosis may be a predictor of better prognosis and point to MALAT1 expression profiling as a candidate biomarker potentially useful in clinical practice.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences, International Journal of Molecular Sciences",
title = "Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia",
number = "2",
pages = "922",
volume = "25",
doi = "10.3390/ijms25020922"
}

Tomić Vujović, K., Ugrin, M., Tošić, N., Vuković, V., Marjanović, I., Kostić, T., Stanković, S., Otašević, V., Šarac, S., Antić, D., Pavlović, S.,& Karan-Đurašević, T.. (2024). Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia. in International Journal of Molecular Sciences
MDPI., 25(2), 922.
https://doi.org/10.3390/ijms25020922

Tomić Vujović K, Ugrin M, Tošić N, Vuković V, Marjanović I, Kostić T, Stanković S, Otašević V, Šarac S, Antić D, Pavlović S, Karan-Đurašević T. Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia. in International Journal of Molecular Sciences. 2024;25(2):922.
doi:10.3390/ijms25020922 .

Tomić Vujović, Kristina, Ugrin, Milena, Tošić, Nataša, Vuković, Vojin, Marjanović, Irena, Kostić, Tatjana, Stanković, Sanja, Otašević, Vladimir, Šarac, Sofija, Antić, Darko, Pavlović, Sonja, Karan-Đurašević, Teodora, "Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia" in International Journal of Molecular Sciences, 25, no. 2 (2024):922,
https://doi.org/10.3390/ijms25020922 . .

TY  - CONF
AU  - Tošić, Nataša
AU  - Ugrin, Milena
AU  - Vuković, Vojin
AU  - Marjanović, Irena
AU  - Kostić, Tatjana
AU  - Antić, Darko
AU  - Stanković, Sanja
AU  - Otašević, Vladimir
AU  - Tomić, Kristina
AU  - Šarac, Sofija
AU  - Mihaljević, Biljana
AU  - Pavlović, Sonja
AU  - Karan-Đurašević, Teodora
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2118
AB  - Introduction: The long non-coding RNA (lncRNA) MALAT1 (metastasis-associated lung adenocarcinoma
transcript 1) dysregulated expression has been reported in a variety of cancers, but has been poorly investigated in chronic lymphocytic leukemia (CLL). The aim of thisstudy wasto investigate the expression
pattern of lncRNA MALAT1 in CLL, and evaluate its prognostic significance.
Methods: MALAT1 expression was analyzed in peripheral blood mononuclear cells of 114 newly-diagnosed CLL patients and 20 healthy controls by qRT-PCR, and association with clinical and biological features at diagnosis was assessed.
Results: MALAT1 was overexpressed in CLL compared to controlsamples(p<0.001). MALAT1 expression
was higher in male patients (p=0.003). It showed no correlation with age, leukocyte, lymphocyte and
platelet count, and serum β2-microglobulin, but exerted a positive correlation with hemoglobin level
(r=0.315, p=0.003) and a negative correlation with lactate dehydrogenase level (r=-0.303, p=0.004).
MALAT1 expression was higher in Binet A and B patients vs. Binet C patients (p=0.037). There was also a
trend toward higher MALAT1 expression in patients with favorable (del13q) and intermediate (normal
karyotype, trisomy12) cytogeneticsin comparison to patients with unfavorable (del11q and del17p) cytogenetics (p=0.059). In addition, high MALAT1 levels were associated with CD38-negative status
(p=0.017), but not with IGHV mutational status. While there was no association with the time to first
treatment, longer median overall survival in MALAT1 high- vs. MALAT1 low-expressing cases was observed (142 vs. 82 months, log rank p=0.032).
Conclusion: LncRNA MALAT1 is up-regulated in CLL. High MALAT1 expression at diagnosis may be associated with better prognosis.
PB  - Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
C3  - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
T1  - Prognostic significance of the long non-coding rna malat1 expression in chronic lymphocytic leukemia
EP  - 60
SP  - 60
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2118
ER  - 

@conference{
author = "Tošić, Nataša and Ugrin, Milena and Vuković, Vojin and Marjanović, Irena and Kostić, Tatjana and Antić, Darko and Stanković, Sanja and Otašević, Vladimir and Tomić, Kristina and Šarac, Sofija and Mihaljević, Biljana and Pavlović, Sonja and Karan-Đurašević, Teodora",
year = "2023",
abstract = "Introduction: The long non-coding RNA (lncRNA) MALAT1 (metastasis-associated lung adenocarcinoma
transcript 1) dysregulated expression has been reported in a variety of cancers, but has been poorly investigated in chronic lymphocytic leukemia (CLL). The aim of thisstudy wasto investigate the expression
pattern of lncRNA MALAT1 in CLL, and evaluate its prognostic significance.
Methods: MALAT1 expression was analyzed in peripheral blood mononuclear cells of 114 newly-diagnosed CLL patients and 20 healthy controls by qRT-PCR, and association with clinical and biological features at diagnosis was assessed.
Results: MALAT1 was overexpressed in CLL compared to controlsamples(p<0.001). MALAT1 expression
was higher in male patients (p=0.003). It showed no correlation with age, leukocyte, lymphocyte and
platelet count, and serum β2-microglobulin, but exerted a positive correlation with hemoglobin level
(r=0.315, p=0.003) and a negative correlation with lactate dehydrogenase level (r=-0.303, p=0.004).
MALAT1 expression was higher in Binet A and B patients vs. Binet C patients (p=0.037). There was also a
trend toward higher MALAT1 expression in patients with favorable (del13q) and intermediate (normal
karyotype, trisomy12) cytogeneticsin comparison to patients with unfavorable (del11q and del17p) cytogenetics (p=0.059). In addition, high MALAT1 levels were associated with CD38-negative status
(p=0.017), but not with IGHV mutational status. While there was no association with the time to first
treatment, longer median overall survival in MALAT1 high- vs. MALAT1 low-expressing cases was observed (142 vs. 82 months, log rank p=0.032).
Conclusion: LncRNA MALAT1 is up-regulated in CLL. High MALAT1 expression at diagnosis may be associated with better prognosis.",
publisher = "Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade",
journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia",
title = "Prognostic significance of the long non-coding rna malat1 expression in chronic lymphocytic leukemia",
pages = "60-60",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2118"
}

Tošić, N., Ugrin, M., Vuković, V., Marjanović, I., Kostić, T., Antić, D., Stanković, S., Otašević, V., Tomić, K., Šarac, S., Mihaljević, B., Pavlović, S.,& Karan-Đurašević, T.. (2023). Prognostic significance of the long non-coding rna malat1 expression in chronic lymphocytic leukemia. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 60-60.
https://hdl.handle.net/21.15107/rcub_imagine_2118

Tošić N, Ugrin M, Vuković V, Marjanović I, Kostić T, Antić D, Stanković S, Otašević V, Tomić K, Šarac S, Mihaljević B, Pavlović S, Karan-Đurašević T. Prognostic significance of the long non-coding rna malat1 expression in chronic lymphocytic leukemia. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:60-60.
https://hdl.handle.net/21.15107/rcub_imagine_2118 .

Tošić, Nataša, Ugrin, Milena, Vuković, Vojin, Marjanović, Irena, Kostić, Tatjana, Antić, Darko, Stanković, Sanja, Otašević, Vladimir, Tomić, Kristina, Šarac, Sofija, Mihaljević, Biljana, Pavlović, Sonja, Karan-Đurašević, Teodora, "Prognostic significance of the long non-coding rna malat1 expression in chronic lymphocytic leukemia" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):60-60,
https://hdl.handle.net/21.15107/rcub_imagine_2118 .

TY  - CONF
AU  - Denčić Fekete, Marija
AU  - Karan-Đurašević, Teodora
AU  - Vuković, Vojin
AU  - Jovanović, Jelica
AU  - Sanader, Senka
AU  - Antić, Darko
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2102
AB  - Chronic lymphocyti c leukemia (CLL) is a malignancy of mature CD5+ B lymphocytes that is characterized by excepti onal
clinical and biological heterogeneity. The Rai and Binet staging systems, developed in the late 1970s to early 1980s,
are used in clinical practi ce to strati fy CLL pati ents into risk categories and to help guide clinical follow-up opti ons: to
treat or to watch and wait. However, in early-stage disease, these systems are unable to predict what pati ents will
face the progression to a more aggressive disease. That means, a number of molecular markers with prognosti c and/
or predicti ve impact exist and their assessment is strongly recommended in all pati ents prior to treatment initi ati on.
One of the fi rst recognized prognosti c genomic aberrati ons in CLL include those detected by fl uorescence in situ
hybridizati on (FISH): del(17p), del(11q), trisomy 12 and del(13q), and the immunoglobulin heavy variable (IGHV) gene
somati c hypermutati on (SHM) status. Moreover, the rapid development of genomics techniques greatly expanded
the understanding of CLL at the molecular level in the past decade. This resulted in the discovery of many newer
prognosti c markers based on chromosomal aberrati ons or gene mutati ons. For instance, next-generati on sequencing
(NGS) studies have led to the discovery of recurrently mutated genes in CLL, such as NOTCH1, SF3B1, BIRC3, XPO1,
POT1, NFKBIE and EGR2, that are associated with poor clinical outcome. Among all of these biomarkers, the disti ncti on
between markers of prognosti c and predicti ve values should be made. Prognosti c markers refer to biomarkers that can
provide informati on regarding the pati ent's outcome regardless of treatment. They are o����� en assessed before treatment
to help guide decisions on to treat or not. Markers associated with overall survival (OS) or ti me to fi rst treatment
(TTFT) represent such examples. On the other hand, predicti ve markers are related to therapeuti c interventi ons
with the ability to predict treatment response to a drug. These markers are normally assessed when pati ents receive
the parti cular therapy. Some markers can be both prognosti c and predicti ve. The Nati onal Comprehensive Cancer
Network guideline recommends testi ng of TP53 geneti c alterati ons, IGHV mutati on status, and several well-established
cytogeneti c markers for CLL prognosti cati on. Of these, TP53 mutati ons, IGHV unmutated status, del(17p), and
del(11q), as well as complex karyotype (the presence of three or more unrelated clonal chromosomal abnormaliti es
in a sample), are associated with poor prognosis. Normal karyotype and trisomy 12 are considered as intermediate
prognosti c factors, whereas del(13q) is associated with a favorable prognosis. The higher frequencies of the
previously menti oned unfavorable markers (except for IGHV) found in the treated populati on usually imply the clonal
evoluti on during disease progression or change in clonal dynamics induced by therapies, especially chemotherapies.
Diff erent molecular and genomic techniques are employed for detecti ng molecular biomarkers in CLL. For IGHV
mutati on status, the preferred method is Sanger sequencing to detect mutati ons in genomic DNA or cDNA following
PCR, and align the resulti ng sequences to the germline IGHV using the IMGT/V-QUEST analyti c tool, where ≥ 98%
homology to the germ line is interpreted as unmutated, >2% nonhomology as mutated, and 97.0% to 97.9% is
interpreted as borderline. Prognosti cally signifi cant chromosomal abnormaliti es are frequently detected using
fl uorescence in situ hybridizati on, array comparati ve genomic hybridizati on or conventi onal karyotyping. Fluorescence
in situ hybridizati on, although off ers a high sensiti vity and specifi city, requires prior knowledge of chromosomal
lesions for the probe designs and are limited to the chosen panel genes. The technique has limitati ons in detecti ng
possible complex cytogeneti c abnormaliti es, as well. On the other hand, karyotyping and array comparati ve genomic
hybridizati on provide genome-wide coverage. Despite the fact that array comparati ve genomic hybridizati on does not
eff ecti vely detect balanced chromosomal rearrangements, it uncovers more genomic abnormaliti es than karyotyping
as the probe-based technology examines the chromosomal structure at a much higher resoluti on. Development in
NGS technology in the past two decades, made the technique, especially targeted sequencing of gene panels, much
less costly and accessible. Currently, in Serbia, geneti c techniques such as FISH, conventi onal karyotyping, Sanger
sequencing and NGS are available for detecti on of CLL biomarkers. Advances in the understanding of CLL pathogenesis
have consequently led to the development of several highly eff ecti ve targeted therapies, including Bruton tyrosine
kinase (BTK), phosphati dylinositol 3-kinase, and BCL2 apoptosis regulator (BCL2) directed inhibitors. B-cell survival
and proliferati on is regulated by the BCR signaling pathway. In normal B cells, BCR is triggered by anti gen ligati on,
leading to acti vati on of a cascade of tyrosine kinases, including BTK. BCR signaling is aberrantly acti vated in many B-cell
malignancies, including CLL. Ibruti nib has demonstrated high clinical effi cacy acti ng as an irreversible potent inhibitor of
Bruton's tyrosine kinase and targets several key components of the BCR pathway. However, despite having 80% to 90%
response rate, 10% to 15% of CLL pati ents, who respond initi ally, develop ibruti nib resistance and disease relapse in 2 to
3 years on ibruti nib treatment, mainly because of the acquisiti on of a BTK C481S mutati on. The mutati on prevents the
drug from forming a covalent bond with the C481 residue that weakened the drug-BTK binding by 500-fold. As a result,
BCR signaling and cell proliferati on were restored in the tumor cells. BTK mutati ons may be found in approximately 70%
of CLL pati ents who progressed on ibruti nib treatment. Another resistance mechanism is through acquired acti vati ng
mutati ons in PLCG2, which is found in approximately 10% of the cases. Given these evidences, the current Nati onal
Comprehensive Cancer Network guideline recommends testi ng for BTK and PLCG2 mutati ons for CLL pati ents receiving
ibruti nib who are suspected of having disease progression. NGS has become the opti mal method for detecti ng BTK
or PLCG2 mutati ons in the se����� ng of ibruti nib treatment, as multi ple mutati ons in both genes may occur in the same
specimen. Currently, approximately 20% of CLL pati ents who progressed on ibruti nib do not have either BTK or PLCG2
mutati ons; thus, with NGS, it is possible to uncover other less common but yet undefi ned drug-resistance mutati ons.
In additi on to BTK and PLCG2 mutati ons known to confer ibruti nib resistance, other molecular markers have
been associated with an upfront high risk of relapse on ibruti nib treatment. It has been reported that complex
karyotype, del(17p)/TP53 mutati on, and del(18p) at baseline before ibruti nib treatment are strongly associated
with disease relapse. Other approved targeted agents for CLL treatment include the phosphati dylinositol 3-kinase
inhibitors idelalisib and duvelisib and BCL2 inhibitor venetoclax. For venetoclax, a novel BCL2-G101V mutati on was
identi fi ed to prevent drug acti vity through drug-protein interacti on. Each pati ent with CLL may have several clinical
and molecular markers of confl icti ng prognosti c signifi cance simultaneously, making the precise prognosti cati on
challenging. Today is of the greatest importance to apply ultrasensiti ve techniques to reveal molecular relapses
a����� er therapy initi ati on and to detect minimal residual disease a����� er pati ents achieve complete responses.
PB  - Belgrade :  Serbian Association on for Cancer Research
C3  - 6th Congress of the Serbian Association for Cancer Research (SDIR)
T1  - Signifi cance of molecular diagnosti cs in therapy of chronic lymphocytic leukemia
EP  - 55
IS  - 1
SP  - 54
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2102
ER  - 

@conference{
author = "Denčić Fekete, Marija and Karan-Đurašević, Teodora and Vuković, Vojin and Jovanović, Jelica and Sanader, Senka and Antić, Darko",
year = "2023",
abstract = "Chronic lymphocyti c leukemia (CLL) is a malignancy of mature CD5+ B lymphocytes that is characterized by excepti onal
clinical and biological heterogeneity. The Rai and Binet staging systems, developed in the late 1970s to early 1980s,
are used in clinical practi ce to strati fy CLL pati ents into risk categories and to help guide clinical follow-up opti ons: to
treat or to watch and wait. However, in early-stage disease, these systems are unable to predict what pati ents will
face the progression to a more aggressive disease. That means, a number of molecular markers with prognosti c and/
or predicti ve impact exist and their assessment is strongly recommended in all pati ents prior to treatment initi ati on.
One of the fi rst recognized prognosti c genomic aberrati ons in CLL include those detected by fl uorescence in situ
hybridizati on (FISH): del(17p), del(11q), trisomy 12 and del(13q), and the immunoglobulin heavy variable (IGHV) gene
somati c hypermutati on (SHM) status. Moreover, the rapid development of genomics techniques greatly expanded
the understanding of CLL at the molecular level in the past decade. This resulted in the discovery of many newer
prognosti c markers based on chromosomal aberrati ons or gene mutati ons. For instance, next-generati on sequencing
(NGS) studies have led to the discovery of recurrently mutated genes in CLL, such as NOTCH1, SF3B1, BIRC3, XPO1,
POT1, NFKBIE and EGR2, that are associated with poor clinical outcome. Among all of these biomarkers, the disti ncti on
between markers of prognosti c and predicti ve values should be made. Prognosti c markers refer to biomarkers that can
provide informati on regarding the pati ent's outcome regardless of treatment. They are o����� en assessed before treatment
to help guide decisions on to treat or not. Markers associated with overall survival (OS) or ti me to fi rst treatment
(TTFT) represent such examples. On the other hand, predicti ve markers are related to therapeuti c interventi ons
with the ability to predict treatment response to a drug. These markers are normally assessed when pati ents receive
the parti cular therapy. Some markers can be both prognosti c and predicti ve. The Nati onal Comprehensive Cancer
Network guideline recommends testi ng of TP53 geneti c alterati ons, IGHV mutati on status, and several well-established
cytogeneti c markers for CLL prognosti cati on. Of these, TP53 mutati ons, IGHV unmutated status, del(17p), and
del(11q), as well as complex karyotype (the presence of three or more unrelated clonal chromosomal abnormaliti es
in a sample), are associated with poor prognosis. Normal karyotype and trisomy 12 are considered as intermediate
prognosti c factors, whereas del(13q) is associated with a favorable prognosis. The higher frequencies of the
previously menti oned unfavorable markers (except for IGHV) found in the treated populati on usually imply the clonal
evoluti on during disease progression or change in clonal dynamics induced by therapies, especially chemotherapies.
Diff erent molecular and genomic techniques are employed for detecti ng molecular biomarkers in CLL. For IGHV
mutati on status, the preferred method is Sanger sequencing to detect mutati ons in genomic DNA or cDNA following
PCR, and align the resulti ng sequences to the germline IGHV using the IMGT/V-QUEST analyti c tool, where ≥ 98%
homology to the germ line is interpreted as unmutated, >2% nonhomology as mutated, and 97.0% to 97.9% is
interpreted as borderline. Prognosti cally signifi cant chromosomal abnormaliti es are frequently detected using
fl uorescence in situ hybridizati on, array comparati ve genomic hybridizati on or conventi onal karyotyping. Fluorescence
in situ hybridizati on, although off ers a high sensiti vity and specifi city, requires prior knowledge of chromosomal
lesions for the probe designs and are limited to the chosen panel genes. The technique has limitati ons in detecti ng
possible complex cytogeneti c abnormaliti es, as well. On the other hand, karyotyping and array comparati ve genomic
hybridizati on provide genome-wide coverage. Despite the fact that array comparati ve genomic hybridizati on does not
eff ecti vely detect balanced chromosomal rearrangements, it uncovers more genomic abnormaliti es than karyotyping
as the probe-based technology examines the chromosomal structure at a much higher resoluti on. Development in
NGS technology in the past two decades, made the technique, especially targeted sequencing of gene panels, much
less costly and accessible. Currently, in Serbia, geneti c techniques such as FISH, conventi onal karyotyping, Sanger
sequencing and NGS are available for detecti on of CLL biomarkers. Advances in the understanding of CLL pathogenesis
have consequently led to the development of several highly eff ecti ve targeted therapies, including Bruton tyrosine
kinase (BTK), phosphati dylinositol 3-kinase, and BCL2 apoptosis regulator (BCL2) directed inhibitors. B-cell survival
and proliferati on is regulated by the BCR signaling pathway. In normal B cells, BCR is triggered by anti gen ligati on,
leading to acti vati on of a cascade of tyrosine kinases, including BTK. BCR signaling is aberrantly acti vated in many B-cell
malignancies, including CLL. Ibruti nib has demonstrated high clinical effi cacy acti ng as an irreversible potent inhibitor of
Bruton's tyrosine kinase and targets several key components of the BCR pathway. However, despite having 80% to 90%
response rate, 10% to 15% of CLL pati ents, who respond initi ally, develop ibruti nib resistance and disease relapse in 2 to
3 years on ibruti nib treatment, mainly because of the acquisiti on of a BTK C481S mutati on. The mutati on prevents the
drug from forming a covalent bond with the C481 residue that weakened the drug-BTK binding by 500-fold. As a result,
BCR signaling and cell proliferati on were restored in the tumor cells. BTK mutati ons may be found in approximately 70%
of CLL pati ents who progressed on ibruti nib treatment. Another resistance mechanism is through acquired acti vati ng
mutati ons in PLCG2, which is found in approximately 10% of the cases. Given these evidences, the current Nati onal
Comprehensive Cancer Network guideline recommends testi ng for BTK and PLCG2 mutati ons for CLL pati ents receiving
ibruti nib who are suspected of having disease progression. NGS has become the opti mal method for detecti ng BTK
or PLCG2 mutati ons in the se����� ng of ibruti nib treatment, as multi ple mutati ons in both genes may occur in the same
specimen. Currently, approximately 20% of CLL pati ents who progressed on ibruti nib do not have either BTK or PLCG2
mutati ons; thus, with NGS, it is possible to uncover other less common but yet undefi ned drug-resistance mutati ons.
In additi on to BTK and PLCG2 mutati ons known to confer ibruti nib resistance, other molecular markers have
been associated with an upfront high risk of relapse on ibruti nib treatment. It has been reported that complex
karyotype, del(17p)/TP53 mutati on, and del(18p) at baseline before ibruti nib treatment are strongly associated
with disease relapse. Other approved targeted agents for CLL treatment include the phosphati dylinositol 3-kinase
inhibitors idelalisib and duvelisib and BCL2 inhibitor venetoclax. For venetoclax, a novel BCL2-G101V mutati on was
identi fi ed to prevent drug acti vity through drug-protein interacti on. Each pati ent with CLL may have several clinical
and molecular markers of confl icti ng prognosti c signifi cance simultaneously, making the precise prognosti cati on
challenging. Today is of the greatest importance to apply ultrasensiti ve techniques to reveal molecular relapses
a����� er therapy initi ati on and to detect minimal residual disease a����� er pati ents achieve complete responses.",
publisher = "Belgrade :  Serbian Association on for Cancer Research",
journal = "6th Congress of the Serbian Association for Cancer Research (SDIR)",
title = "Signifi cance of molecular diagnosti cs in therapy of chronic lymphocytic leukemia",
pages = "55-54",
number = "1",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2102"
}

Denčić Fekete, M., Karan-Đurašević, T., Vuković, V., Jovanović, J., Sanader, S.,& Antić, D.. (2023). Signifi cance of molecular diagnosti cs in therapy of chronic lymphocytic leukemia. in 6th Congress of the Serbian Association for Cancer Research (SDIR)
Belgrade :  Serbian Association on for Cancer Research.(1), 54-55.
https://hdl.handle.net/21.15107/rcub_imagine_2102

Denčić Fekete M, Karan-Đurašević T, Vuković V, Jovanović J, Sanader S, Antić D. Signifi cance of molecular diagnosti cs in therapy of chronic lymphocytic leukemia. in 6th Congress of the Serbian Association for Cancer Research (SDIR). 2023;(1):54-55.
https://hdl.handle.net/21.15107/rcub_imagine_2102 .

Denčić Fekete, Marija, Karan-Đurašević, Teodora, Vuković, Vojin, Jovanović, Jelica, Sanader, Senka, Antić, Darko, "Signifi cance of molecular diagnosti cs in therapy of chronic lymphocytic leukemia" in 6th Congress of the Serbian Association for Cancer Research (SDIR), no. 1 (2023):54-55,
https://hdl.handle.net/21.15107/rcub_imagine_2102 .

TY  - CONF
AU  - Karan-Đurašević, Teodora
AU  - Ugrin, Milena
AU  - Vuković, Vojin
AU  - Antić, Darko
AU  - Stanković, Sanja
AU  - Marjanović, Irena
AU  - Kostić, Tatjana
AU  - Otasević, Vladimir
AU  - Tomić, Kristina
AU  - Sarać, Sofija
AU  - Mihaljević, Biljana
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2023
UR  - https://journals.lww.com/hemasphere/fulltext/2023/08003/pb1917__expression_of_the_long_non_coding_rna.1797.aspx
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2155
AB  - Background: The long non-coding RNA (lncRNA) MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) dysregulated expression and prognostic significance have been reported in a variety of cancers, including hematological malignancies, but have been poorly investigated in chronic lymphocytic leukemia (CLL). Acting through regulation of gene expression at transcriptional and post-transcriptional level, lncRNA MALAT1 is involved in many cellular processes such as proliferation, apoptosis, migration and drug resistance. However, its role as either an oncogene or a tumor-supressor is still controversial, and clearly tumor type-dependent.  Aims: To analyze the expression pattern of lncRNA MALAT1 in CLL, and evaluate its prognostic relevance.  Methods: This study enrolled 114 unselected CLL patients (pts) and 20 healthy controls (hcs). Clinical and laboratory characteristics of pts were determined at diagnosis, while genetic analyses were performed during the period prior to first treatment. The expression of MALAT1 was analyzed in peripheral blood mononuclear cells by RQ-PCR, using TaqMan chemistry and GAPDH as endogenous control; relative quantification was made by comparative ddCt method, using hcs as calibrator.  Results: CLL cohort consisted of 81 males and 33 females (male/female=2.45), with median age at diagnosis of 59 years (range 33-80). Hcs group consisted of 15 males and 5 females (male/female=3), with median age at diagnosis of 71 years (range 65-85). Distribution of Binet stages (112/114 pts) was as follows: A-46.4%, B-39.3%, C-14.3%. Del13q, normal karyotype, trisomy12, del11q and del17p were detected by FISH in 33%, 35%, 9.3%, 10.3% and 12.4% of pts, respectively (97/114 pts). CD38 status (85/114 pts) was negative in 70.6% and positive in 29.4% of pts. Regarding IGHV mutational status (114 pts), 41.2% of pts were mutated, and 58.8% unmutated. Median follow-up was 72 months (range 1-360). LncRNA MALAT1 was overexpressed in CLL pts compared to hcs (p<0.001). Median value of MALAT1 expression was used to divide the cohort into MALAT1low and MALAT1high groups, and association with clinical and biological features at diagnosis was assessed. In both pts and hcs MALAT1 expression was not associated with age but, unlike hcs, MALAT1high status was significantly associated with male sex in CLL (p=0.003). Regarding laboratory parameters, MALAT1 expression showed no correlation with leukocyte, lymphocyte and platelet counts, and serum β2-microglobulin, but exerted a positive correlation with hemoglobin level (r=0.315, p=0.003) and a negative correlation with lactate dehydrogenase (LDH) level (r=-0.303, p=0.004). MALAT1 expression was higher in Binet A and B pts vs. Binet C pts (p=0.037). There was also a trend toward higher MALAT1 expression in pts with favorable (del13q) and intermediate (normal karyotype, trisomy12) cytogenetics in comparison to pts with unfavorable (del11q and del17p) cytogenetics (p=0.059). In addition, MALAT1high status was associated with CD38-negative status (p=0.017), but not with IGHV mutational status. Finally, while the association of MALAT1 expression with the time to first treatment was not detected, longer median overall survival (OS) in MALAT1high vs. MALAT1low group was observed (142 vs. 82 months, log rank p=0.032).  Summary/Conclusion: LncRNA MALAT1 is up-regulated in CLL. However, high MALAT1 expression is associated with several favorable prognostic markers (high hemoglobin, low LDH, early clinical stages, negative CD38 status), as well as longer OS. The exact mechanisms of MALAT1 function in CLL pathogenesis and/or progression remain to be determined.
C3  - HemaSphere
T1  - PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA
IS  - S3
SP  - e1785725
VL  - 7
DO  - 10.1097/01.HS9.0000974492.17857.25
ER  - 

@conference{
author = "Karan-Đurašević, Teodora and Ugrin, Milena and Vuković, Vojin and Antić, Darko and Stanković, Sanja and Marjanović, Irena and Kostić, Tatjana and Otasević, Vladimir and Tomić, Kristina and Sarać, Sofija and Mihaljević, Biljana and Pavlović, Sonja and Tošić, Nataša",
year = "2023",
abstract = "Background: The long non-coding RNA (lncRNA) MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) dysregulated expression and prognostic significance have been reported in a variety of cancers, including hematological malignancies, but have been poorly investigated in chronic lymphocytic leukemia (CLL). Acting through regulation of gene expression at transcriptional and post-transcriptional level, lncRNA MALAT1 is involved in many cellular processes such as proliferation, apoptosis, migration and drug resistance. However, its role as either an oncogene or a tumor-supressor is still controversial, and clearly tumor type-dependent.  Aims: To analyze the expression pattern of lncRNA MALAT1 in CLL, and evaluate its prognostic relevance.  Methods: This study enrolled 114 unselected CLL patients (pts) and 20 healthy controls (hcs). Clinical and laboratory characteristics of pts were determined at diagnosis, while genetic analyses were performed during the period prior to first treatment. The expression of MALAT1 was analyzed in peripheral blood mononuclear cells by RQ-PCR, using TaqMan chemistry and GAPDH as endogenous control; relative quantification was made by comparative ddCt method, using hcs as calibrator.  Results: CLL cohort consisted of 81 males and 33 females (male/female=2.45), with median age at diagnosis of 59 years (range 33-80). Hcs group consisted of 15 males and 5 females (male/female=3), with median age at diagnosis of 71 years (range 65-85). Distribution of Binet stages (112/114 pts) was as follows: A-46.4%, B-39.3%, C-14.3%. Del13q, normal karyotype, trisomy12, del11q and del17p were detected by FISH in 33%, 35%, 9.3%, 10.3% and 12.4% of pts, respectively (97/114 pts). CD38 status (85/114 pts) was negative in 70.6% and positive in 29.4% of pts. Regarding IGHV mutational status (114 pts), 41.2% of pts were mutated, and 58.8% unmutated. Median follow-up was 72 months (range 1-360). LncRNA MALAT1 was overexpressed in CLL pts compared to hcs (p<0.001). Median value of MALAT1 expression was used to divide the cohort into MALAT1low and MALAT1high groups, and association with clinical and biological features at diagnosis was assessed. In both pts and hcs MALAT1 expression was not associated with age but, unlike hcs, MALAT1high status was significantly associated with male sex in CLL (p=0.003). Regarding laboratory parameters, MALAT1 expression showed no correlation with leukocyte, lymphocyte and platelet counts, and serum β2-microglobulin, but exerted a positive correlation with hemoglobin level (r=0.315, p=0.003) and a negative correlation with lactate dehydrogenase (LDH) level (r=-0.303, p=0.004). MALAT1 expression was higher in Binet A and B pts vs. Binet C pts (p=0.037). There was also a trend toward higher MALAT1 expression in pts with favorable (del13q) and intermediate (normal karyotype, trisomy12) cytogenetics in comparison to pts with unfavorable (del11q and del17p) cytogenetics (p=0.059). In addition, MALAT1high status was associated with CD38-negative status (p=0.017), but not with IGHV mutational status. Finally, while the association of MALAT1 expression with the time to first treatment was not detected, longer median overall survival (OS) in MALAT1high vs. MALAT1low group was observed (142 vs. 82 months, log rank p=0.032).  Summary/Conclusion: LncRNA MALAT1 is up-regulated in CLL. However, high MALAT1 expression is associated with several favorable prognostic markers (high hemoglobin, low LDH, early clinical stages, negative CD38 status), as well as longer OS. The exact mechanisms of MALAT1 function in CLL pathogenesis and/or progression remain to be determined.",
journal = "HemaSphere",
title = "PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA",
number = "S3",
pages = "e1785725",
volume = "7",
doi = "10.1097/01.HS9.0000974492.17857.25"
}

Karan-Đurašević, T., Ugrin, M., Vuković, V., Antić, D., Stanković, S., Marjanović, I., Kostić, T., Otasević, V., Tomić, K., Sarać, S., Mihaljević, B., Pavlović, S.,& Tošić, N.. (2023). PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA. in HemaSphere, 7(S3), e1785725.
https://doi.org/10.1097/01.HS9.0000974492.17857.25

Karan-Đurašević T, Ugrin M, Vuković V, Antić D, Stanković S, Marjanović I, Kostić T, Otasević V, Tomić K, Sarać S, Mihaljević B, Pavlović S, Tošić N. PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA. in HemaSphere. 2023;7(S3):e1785725.
doi:10.1097/01.HS9.0000974492.17857.25 .

Karan-Đurašević, Teodora, Ugrin, Milena, Vuković, Vojin, Antić, Darko, Stanković, Sanja, Marjanović, Irena, Kostić, Tatjana, Otasević, Vladimir, Tomić, Kristina, Sarać, Sofija, Mihaljević, Biljana, Pavlović, Sonja, Tošić, Nataša, "PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA" in HemaSphere, 7, no. S3 (2023):e1785725,
https://doi.org/10.1097/01.HS9.0000974492.17857.25 . .

TY  - JOUR
AU  - Tošić, Nataša
AU  - Ugrin, Milena
AU  - Marjanović, Irena
AU  - Kostić, Tatjana
AU  - Vuković, Vojin
AU  - Tomić, Kristina
AU  - Otasević, Vladimir
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Pavlović, Sonja
AU  - Karan-Đurašević, Teodora
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1510
AB  - Introduction The B-cell lymphoma/leukaemia 11A (BCL11A) gene encodes a Kruppel-like transcription factor involved in lymphocyte development during normal haematopoiesis. Aberrant expression of BCL11A has been observed in several haematological malignancies, including chronic lymphocytic leukaemia (CLL). However, its functions in the regulatory networks of malignant B lymphocytes are poorly understood, as are the relations to clinical course and outcome of B-cell malignancies, particularly CLL. Methods The expression of BCL11A was analysed in peripheral blood mononuclear cells of 87 newly-diagnosed CLL patients by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), and association with clinical and molecular variables was assessed. Results BCL11A was significantly overexpressed in CLL samples compared to control samples (p  lt  0.001). BCL11A expression level exhibited no association with age, sex, leukocyte, lymphocyte and platelet counts, haemoglobin level, serum beta 2-microglobulin, CD38 status and cytogenetic abnormalities. On the other hand, high BCL11A expression was associated with low serum lactate dehydrogenase (p = 0.031), Binet A stage (p = 0.047) and mutated IGHV (p = 0.028). In addition, a positive correlation with BCL2/BAX mRNA ratio was observed (r = 0.36; p  lt  0.001). Regarding the association with the time to first treatment (TTFT), a trend towards longer median TTFT in BCL11A high- versus BCL11A low-expressing cases was detected (21 vs. 6 months; p = 0.164). Conclusion The results of this study show that BCL11A is upregulated in CLL patients, and that high BCL11A expression at diagnosis may be associated with better prognosis. These data are consistent with the role of BCL11A expression in CLL biology, and imply its potential prognostic relevance.
PB  - Wiley, Hoboken
T2  - International Journal of Laboratory Hematology
T1  - Expression of BCL11A in chronic lymphocytic leukaemia
EP  - 71
IS  - 1
SP  - 64
VL  - 45
DO  - 10.1111/ijlh.13969
ER  - 

@article{
author = "Tošić, Nataša and Ugrin, Milena and Marjanović, Irena and Kostić, Tatjana and Vuković, Vojin and Tomić, Kristina and Otasević, Vladimir and Antić, Darko and Mihaljević, Biljana and Pavlović, Sonja and Karan-Đurašević, Teodora",
year = "2023",
abstract = "Introduction The B-cell lymphoma/leukaemia 11A (BCL11A) gene encodes a Kruppel-like transcription factor involved in lymphocyte development during normal haematopoiesis. Aberrant expression of BCL11A has been observed in several haematological malignancies, including chronic lymphocytic leukaemia (CLL). However, its functions in the regulatory networks of malignant B lymphocytes are poorly understood, as are the relations to clinical course and outcome of B-cell malignancies, particularly CLL. Methods The expression of BCL11A was analysed in peripheral blood mononuclear cells of 87 newly-diagnosed CLL patients by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), and association with clinical and molecular variables was assessed. Results BCL11A was significantly overexpressed in CLL samples compared to control samples (p  lt  0.001). BCL11A expression level exhibited no association with age, sex, leukocyte, lymphocyte and platelet counts, haemoglobin level, serum beta 2-microglobulin, CD38 status and cytogenetic abnormalities. On the other hand, high BCL11A expression was associated with low serum lactate dehydrogenase (p = 0.031), Binet A stage (p = 0.047) and mutated IGHV (p = 0.028). In addition, a positive correlation with BCL2/BAX mRNA ratio was observed (r = 0.36; p  lt  0.001). Regarding the association with the time to first treatment (TTFT), a trend towards longer median TTFT in BCL11A high- versus BCL11A low-expressing cases was detected (21 vs. 6 months; p = 0.164). Conclusion The results of this study show that BCL11A is upregulated in CLL patients, and that high BCL11A expression at diagnosis may be associated with better prognosis. These data are consistent with the role of BCL11A expression in CLL biology, and imply its potential prognostic relevance.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Laboratory Hematology",
title = "Expression of BCL11A in chronic lymphocytic leukaemia",
pages = "71-64",
number = "1",
volume = "45",
doi = "10.1111/ijlh.13969"
}

Tošić, N., Ugrin, M., Marjanović, I., Kostić, T., Vuković, V., Tomić, K., Otasević, V., Antić, D., Mihaljević, B., Pavlović, S.,& Karan-Đurašević, T.. (2023). Expression of BCL11A in chronic lymphocytic leukaemia. in International Journal of Laboratory Hematology
Wiley, Hoboken., 45(1), 64-71.
https://doi.org/10.1111/ijlh.13969

Tošić N, Ugrin M, Marjanović I, Kostić T, Vuković V, Tomić K, Otasević V, Antić D, Mihaljević B, Pavlović S, Karan-Đurašević T. Expression of BCL11A in chronic lymphocytic leukaemia. in International Journal of Laboratory Hematology. 2023;45(1):64-71.
doi:10.1111/ijlh.13969 .

Tošić, Nataša, Ugrin, Milena, Marjanović, Irena, Kostić, Tatjana, Vuković, Vojin, Tomić, Kristina, Otasević, Vladimir, Antić, Darko, Mihaljević, Biljana, Pavlović, Sonja, Karan-Đurašević, Teodora, "Expression of BCL11A in chronic lymphocytic leukaemia" in International Journal of Laboratory Hematology, 45, no. 1 (2023):64-71,
https://doi.org/10.1111/ijlh.13969 . .

TY  - JOUR
AU  - Mihaljević, Biljana
AU  - Vuković, Vojin
AU  - Milić, Nataša
AU  - Karan-Đurašević, Teodora
AU  - Tošić, Nataša
AU  - Kostić, Tatjana
AU  - Marjanović, Irena
AU  - Denčić-Fekete, Marija
AU  - Đurašinović, Vladislava
AU  - Dragović-Ivančević, Tijana
AU  - Pavlović, Sonja
AU  - Antić, Darko
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1458
AB  - Uvod/Cilj Prognoza hronične limfocitne leukemije (HLL) značajno je unapređena u poslednje vreme. Među nekoliko prognostičkih modela čiji je cilj predviđanje vremena do prve terapije (eng. TTFT) izdvajaju se skor rizika od progresije (eng. PRS) i skor Centra za rak MD Anderson iz 2011. God. (eng. MDACC 2011), dok se internacionalni prognostički indeks za HLL (eng. CLL-IPI), iako primarno ustanovljen za predikciju ukupnog preživljavanja (eng. OS), dobro pokazao i u predikciji TTFT. Cilj ovog rada je da se ispita značaj pomenutih prognostičkih modela u pogledu predviđanja TTFT i OS. Metode Analizirana kohorta je obuhvatila 57 neselektovanih bolesnika sa HLL Univerzitetskog kliničkog centra Srbije sa prosečno agresivnijim profilom bolesti u odnosu na opštu populaciju de novo bolesnika sa HLL. Bolesnici su ocenjivani prema navedenim skorovima uz analizu TTFT i OS. Rezultati Bolesnici sa višim vrednostima CLL-IPI, PRS i MDACC 2011 primili su prvu terapiju značajno ranije u poređenju sa bolesnicima sa nižim vrednostima ovih skorova (p = 0,002, p = 0,019 i p  lt  0,001, redom). U multivarijantnoj analizi, MDACC 2011 i CLL-IPI su zadržali prognostički značaj u predikciji TTFT (p = 0,001, odnosno p = 0,018), dok je PRS ovaj značaj izgubio. CLL-IPI je bio jedini značajan prediktor OS u univarijantnoj (p = 0,005) i u multivarijantnoj analizi (p = 0,013). Zaključak CLL-IPI, PRS i naročito MDACC 2011 su dobri prediktori TTFT čak i u kohortama bolesnika sa agresivnijom bolešću, dok je za predikciju OS od ova tri prognostička modela CLL-IPI jedini primenljiv. Ovi rezultati pokazuju da bi prognostičke modele trebalo ispitati na bolesnicima sa HLL u različitim fazama bolesti, kakvi se sreću u realnoj kliničkoj praksi.
AB  - Introduction/Objective Prognostication of chronic lymphocytic leukemia (CLL) has been substantially improved in recent times. Among several prognostic models (PMs) focused on the prediction of time to first treatment (TTFT), progression-risk score (PRS), and MD Anderson Cancer Center score 2011 (MDACC 2011) are the most relevant, while CLL-International Prognostic Index (CLL-IPI), although originally developed to predict overall survival (OS), is also being used to estimate TTFT. The aim of this study was to investigate CLL-IPI, PRS, and MDACC 2011 prognostic values regarding TTFT and OS. Methods The analyzed cohort included 57 unselected Serbian CLL patients from a single institution, with the basic characteristics reflecting more aggressive disease than in the general de novo CLL population. The eligible patients were assigned investigated PMs, and TTFT and OS analyses were performed. Results Patients with higher risk scores according to CLL-IPI, PRS, and MDACC 2011 underwent treatment significantly earlier than patients with lower risk scores (p = 0.002, p = 0.019, and p  lt  0.001, respectively). In multivariate analysis, MDACC 2011 and CLL-IPI retained their significance regarding TTFT (p = 0.001 and p = 0.018, respectively), while PRS did not. CLL-IPI was the only significant predictor of OS both at the univariate (p = 0.005) and multivariate (p = 0.013) levels. Conclusion CLL-IPI, PRS, and particularly MDACC 2011 are able to predict TTFT even in cohorts with more advanced-disease patients, while for prediction of OS, CLL-IPI is the only applicable among the three PMs. These results imply that PMs should be investigated in more diverse CLL populations, as it is in real-life setting.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra
T1  - Comparative analysis of International Prognostic Index for chronic lymphocytic leukemia, progression-risk score, and MD Anderson Cancer Center 2011 score: A single center experience
EP  - 421
IS  - 7-8
SP  - 415
VL  - 149
DO  - 10.2298/SARH201005047M
ER  - 

@article{
author = "Mihaljević, Biljana and Vuković, Vojin and Milić, Nataša and Karan-Đurašević, Teodora and Tošić, Nataša and Kostić, Tatjana and Marjanović, Irena and Denčić-Fekete, Marija and Đurašinović, Vladislava and Dragović-Ivančević, Tijana and Pavlović, Sonja and Antić, Darko",
year = "2021",
abstract = "Uvod/Cilj Prognoza hronične limfocitne leukemije (HLL) značajno je unapređena u poslednje vreme. Među nekoliko prognostičkih modela čiji je cilj predviđanje vremena do prve terapije (eng. TTFT) izdvajaju se skor rizika od progresije (eng. PRS) i skor Centra za rak MD Anderson iz 2011. God. (eng. MDACC 2011), dok se internacionalni prognostički indeks za HLL (eng. CLL-IPI), iako primarno ustanovljen za predikciju ukupnog preživljavanja (eng. OS), dobro pokazao i u predikciji TTFT. Cilj ovog rada je da se ispita značaj pomenutih prognostičkih modela u pogledu predviđanja TTFT i OS. Metode Analizirana kohorta je obuhvatila 57 neselektovanih bolesnika sa HLL Univerzitetskog kliničkog centra Srbije sa prosečno agresivnijim profilom bolesti u odnosu na opštu populaciju de novo bolesnika sa HLL. Bolesnici su ocenjivani prema navedenim skorovima uz analizu TTFT i OS. Rezultati Bolesnici sa višim vrednostima CLL-IPI, PRS i MDACC 2011 primili su prvu terapiju značajno ranije u poređenju sa bolesnicima sa nižim vrednostima ovih skorova (p = 0,002, p = 0,019 i p  lt  0,001, redom). U multivarijantnoj analizi, MDACC 2011 i CLL-IPI su zadržali prognostički značaj u predikciji TTFT (p = 0,001, odnosno p = 0,018), dok je PRS ovaj značaj izgubio. CLL-IPI je bio jedini značajan prediktor OS u univarijantnoj (p = 0,005) i u multivarijantnoj analizi (p = 0,013). Zaključak CLL-IPI, PRS i naročito MDACC 2011 su dobri prediktori TTFT čak i u kohortama bolesnika sa agresivnijom bolešću, dok je za predikciju OS od ova tri prognostička modela CLL-IPI jedini primenljiv. Ovi rezultati pokazuju da bi prognostičke modele trebalo ispitati na bolesnicima sa HLL u različitim fazama bolesti, kakvi se sreću u realnoj kliničkoj praksi., Introduction/Objective Prognostication of chronic lymphocytic leukemia (CLL) has been substantially improved in recent times. Among several prognostic models (PMs) focused on the prediction of time to first treatment (TTFT), progression-risk score (PRS), and MD Anderson Cancer Center score 2011 (MDACC 2011) are the most relevant, while CLL-International Prognostic Index (CLL-IPI), although originally developed to predict overall survival (OS), is also being used to estimate TTFT. The aim of this study was to investigate CLL-IPI, PRS, and MDACC 2011 prognostic values regarding TTFT and OS. Methods The analyzed cohort included 57 unselected Serbian CLL patients from a single institution, with the basic characteristics reflecting more aggressive disease than in the general de novo CLL population. The eligible patients were assigned investigated PMs, and TTFT and OS analyses were performed. Results Patients with higher risk scores according to CLL-IPI, PRS, and MDACC 2011 underwent treatment significantly earlier than patients with lower risk scores (p = 0.002, p = 0.019, and p  lt  0.001, respectively). In multivariate analysis, MDACC 2011 and CLL-IPI retained their significance regarding TTFT (p = 0.001 and p = 0.018, respectively), while PRS did not. CLL-IPI was the only significant predictor of OS both at the univariate (p = 0.005) and multivariate (p = 0.013) levels. Conclusion CLL-IPI, PRS, and particularly MDACC 2011 are able to predict TTFT even in cohorts with more advanced-disease patients, while for prediction of OS, CLL-IPI is the only applicable among the three PMs. These results imply that PMs should be investigated in more diverse CLL populations, as it is in real-life setting.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra, Comparative analysis of International Prognostic Index for chronic lymphocytic leukemia, progression-risk score, and MD Anderson Cancer Center 2011 score: A single center experience",
pages = "421-415",
number = "7-8",
volume = "149",
doi = "10.2298/SARH201005047M"
}

Mihaljević, B., Vuković, V., Milić, N., Karan-Đurašević, T., Tošić, N., Kostić, T., Marjanović, I., Denčić-Fekete, M., Đurašinović, V., Dragović-Ivančević, T., Pavlović, S.,& Antić, D.. (2021). Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 149(7-8), 415-421.
https://doi.org/10.2298/SARH201005047M

Mihaljević B, Vuković V, Milić N, Karan-Đurašević T, Tošić N, Kostić T, Marjanović I, Denčić-Fekete M, Đurašinović V, Dragović-Ivančević T, Pavlović S, Antić D. Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra. in Srpski arhiv za celokupno lekarstvo. 2021;149(7-8):415-421.
doi:10.2298/SARH201005047M .

Mihaljević, Biljana, Vuković, Vojin, Milić, Nataša, Karan-Đurašević, Teodora, Tošić, Nataša, Kostić, Tatjana, Marjanović, Irena, Denčić-Fekete, Marija, Đurašinović, Vladislava, Dragović-Ivančević, Tijana, Pavlović, Sonja, Antić, Darko, "Uporedna analiza internacionalnog prognostičkog indeksa za hroničnu limfocitnu leukemiju, skora rizika od progresije i skora Centra za rak MD Anderson - iskustvo jednog centra" in Srpski arhiv za celokupno lekarstvo, 149, no. 7-8 (2021):415-421,
https://doi.org/10.2298/SARH201005047M . .

TY  - JOUR
AU  - Agathangelidis, Andreas
AU  - Chatzidimitriou, Anastasia
AU  - Gemenetzi, Katerina
AU  - Giudicelli, Veronique
AU  - Karypidou, Maria
AU  - Plevova, Karla
AU  - Davis, Zadie
AU  - Yan, Xiao-Jie
AU  - Jeromin, Sabine
AU  - Schneider, Christof
AU  - Pedersen, Lone Bredo
AU  - Tschumper, Renee C.
AU  - Sutton, Lesley-Ann
AU  - Baliakas, Panagiotis
AU  - Scarfo, Lydia
AU  - van Gastel, Ellen J.
AU  - Armand, Marine
AU  - Tausch, Eugen
AU  - Biderman, Bella
AU  - Baer, Constance
AU  - Bagnara, Davide
AU  - Navarro, Alba
AU  - de Septenville, Anne Langlois
AU  - Guido, Valentina
AU  - Mitterbauer-Hohendanner, Gerlinde
AU  - Dimovski, Aleksandar
AU  - Brieghel, Christian
AU  - Lawless, Sarah
AU  - Meggendorfer, Manja
AU  - Brazdilova, Kamila
AU  - Ritgen, Matthias
AU  - Facco, Monica
AU  - Tresoldi, Cristina
AU  - Visentin, Andrea
AU  - Patriarca, Andrea
AU  - Catherwood, Mark
AU  - Bonello, Lisa
AU  - Sudarikov, Andrey
AU  - Vanura, Katrina
AU  - Roumelioti, Maria
AU  - Francova, Hana Skuhrova
AU  - Moysiadis, Theodoros
AU  - Veronese, Silvio
AU  - Giannopoulos, Krzysztof
AU  - Mansouri, Larry
AU  - Karan-Đurašević, Teodora
AU  - Sandaltzopoulos, Raphael
AU  - Bodor, Csaba
AU  - Fais, Franco
AU  - Kater, Arnon
AU  - Panovska, Irina
AU  - Rossi, Davide
AU  - Alshemmari, Salem
AU  - Panagiotidis, Panagiotis
AU  - Costeas, Paul
AU  - Espinet, Blanca
AU  - Antić, Darko
AU  - Foroni, Letizia
AU  - Montillo, Marco
AU  - Trentin, Livio
AU  - Stavroyianni, Niki
AU  - Gaidano, Gianluca
AU  - di Celle, Paola Francia
AU  - Niemann, Carsten
AU  - Campo, Elias
AU  - Anagnostopoulos, Achilles
AU  - Pott, Christiane
AU  - Fischer, Kirsten
AU  - Hallek, Michael
AU  - Oscier, David
AU  - Stilgenbauer, Stephan
AU  - Haferlach, Claudia
AU  - Jelinek, Diane
AU  - Chiorazzi, Nicholas
AU  - Pospisilova, Sarka
AU  - Lefranc, Marie-Paule
AU  - Kossida, Sofia
AU  - Langerak, Anton W.
AU  - Belessi, Chrysoula
AU  - Davi, Frederic
AU  - Rosenquist, Richard
AU  - Ghia, Paolo
AU  - Stamatopoulos, Kostas
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1427
AB  - Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed "satellites," were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.
PB  - Amer Soc Hematology, Washington
T2  - Blood
T1  - Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
EP  - 1376
IS  - 10
SP  - 1365
VL  - 137
DO  - 10.1182/blood.2020007039
ER  - 

@article{
author = "Agathangelidis, Andreas and Chatzidimitriou, Anastasia and Gemenetzi, Katerina and Giudicelli, Veronique and Karypidou, Maria and Plevova, Karla and Davis, Zadie and Yan, Xiao-Jie and Jeromin, Sabine and Schneider, Christof and Pedersen, Lone Bredo and Tschumper, Renee C. and Sutton, Lesley-Ann and Baliakas, Panagiotis and Scarfo, Lydia and van Gastel, Ellen J. and Armand, Marine and Tausch, Eugen and Biderman, Bella and Baer, Constance and Bagnara, Davide and Navarro, Alba and de Septenville, Anne Langlois and Guido, Valentina and Mitterbauer-Hohendanner, Gerlinde and Dimovski, Aleksandar and Brieghel, Christian and Lawless, Sarah and Meggendorfer, Manja and Brazdilova, Kamila and Ritgen, Matthias and Facco, Monica and Tresoldi, Cristina and Visentin, Andrea and Patriarca, Andrea and Catherwood, Mark and Bonello, Lisa and Sudarikov, Andrey and Vanura, Katrina and Roumelioti, Maria and Francova, Hana Skuhrova and Moysiadis, Theodoros and Veronese, Silvio and Giannopoulos, Krzysztof and Mansouri, Larry and Karan-Đurašević, Teodora and Sandaltzopoulos, Raphael and Bodor, Csaba and Fais, Franco and Kater, Arnon and Panovska, Irina and Rossi, Davide and Alshemmari, Salem and Panagiotidis, Panagiotis and Costeas, Paul and Espinet, Blanca and Antić, Darko and Foroni, Letizia and Montillo, Marco and Trentin, Livio and Stavroyianni, Niki and Gaidano, Gianluca and di Celle, Paola Francia and Niemann, Carsten and Campo, Elias and Anagnostopoulos, Achilles and Pott, Christiane and Fischer, Kirsten and Hallek, Michael and Oscier, David and Stilgenbauer, Stephan and Haferlach, Claudia and Jelinek, Diane and Chiorazzi, Nicholas and Pospisilova, Sarka and Lefranc, Marie-Paule and Kossida, Sofia and Langerak, Anton W. and Belessi, Chrysoula and Davi, Frederic and Rosenquist, Richard and Ghia, Paolo and Stamatopoulos, Kostas",
year = "2021",
abstract = "Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed "satellites," were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.",
publisher = "Amer Soc Hematology, Washington",
journal = "Blood",
title = "Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL",
pages = "1376-1365",
number = "10",
volume = "137",
doi = "10.1182/blood.2020007039"
}

Agathangelidis, A., Chatzidimitriou, A., Gemenetzi, K., Giudicelli, V., Karypidou, M., Plevova, K., Davis, Z., Yan, X., Jeromin, S., Schneider, C., Pedersen, L. B., Tschumper, R. C., Sutton, L., Baliakas, P., Scarfo, L., van Gastel, E. J., Armand, M., Tausch, E., Biderman, B., Baer, C., Bagnara, D., Navarro, A., de Septenville, A. L., Guido, V., Mitterbauer-Hohendanner, G., Dimovski, A., Brieghel, C., Lawless, S., Meggendorfer, M., Brazdilova, K., Ritgen, M., Facco, M., Tresoldi, C., Visentin, A., Patriarca, A., Catherwood, M., Bonello, L., Sudarikov, A., Vanura, K., Roumelioti, M., Francova, H. S., Moysiadis, T., Veronese, S., Giannopoulos, K., Mansouri, L., Karan-Đurašević, T., Sandaltzopoulos, R., Bodor, C., Fais, F., Kater, A., Panovska, I., Rossi, D., Alshemmari, S., Panagiotidis, P., Costeas, P., Espinet, B., Antić, D., Foroni, L., Montillo, M., Trentin, L., Stavroyianni, N., Gaidano, G., di Celle, P. F., Niemann, C., Campo, E., Anagnostopoulos, A., Pott, C., Fischer, K., Hallek, M., Oscier, D., Stilgenbauer, S., Haferlach, C., Jelinek, D., Chiorazzi, N., Pospisilova, S., Lefranc, M., Kossida, S., Langerak, A. W., Belessi, C., Davi, F., Rosenquist, R., Ghia, P.,& Stamatopoulos, K.. (2021). Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. in Blood
Amer Soc Hematology, Washington., 137(10), 1365-1376.
https://doi.org/10.1182/blood.2020007039

Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, Davis Z, Yan X, Jeromin S, Schneider C, Pedersen LB, Tschumper RC, Sutton L, Baliakas P, Scarfo L, van Gastel EJ, Armand M, Tausch E, Biderman B, Baer C, Bagnara D, Navarro A, de Septenville AL, Guido V, Mitterbauer-Hohendanner G, Dimovski A, Brieghel C, Lawless S, Meggendorfer M, Brazdilova K, Ritgen M, Facco M, Tresoldi C, Visentin A, Patriarca A, Catherwood M, Bonello L, Sudarikov A, Vanura K, Roumelioti M, Francova HS, Moysiadis T, Veronese S, Giannopoulos K, Mansouri L, Karan-Đurašević T, Sandaltzopoulos R, Bodor C, Fais F, Kater A, Panovska I, Rossi D, Alshemmari S, Panagiotidis P, Costeas P, Espinet B, Antić D, Foroni L, Montillo M, Trentin L, Stavroyianni N, Gaidano G, di Celle PF, Niemann C, Campo E, Anagnostopoulos A, Pott C, Fischer K, Hallek M, Oscier D, Stilgenbauer S, Haferlach C, Jelinek D, Chiorazzi N, Pospisilova S, Lefranc M, Kossida S, Langerak AW, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. in Blood. 2021;137(10):1365-1376.
doi:10.1182/blood.2020007039 .

Agathangelidis, Andreas, Chatzidimitriou, Anastasia, Gemenetzi, Katerina, Giudicelli, Veronique, Karypidou, Maria, Plevova, Karla, Davis, Zadie, Yan, Xiao-Jie, Jeromin, Sabine, Schneider, Christof, Pedersen, Lone Bredo, Tschumper, Renee C., Sutton, Lesley-Ann, Baliakas, Panagiotis, Scarfo, Lydia, van Gastel, Ellen J., Armand, Marine, Tausch, Eugen, Biderman, Bella, Baer, Constance, Bagnara, Davide, Navarro, Alba, de Septenville, Anne Langlois, Guido, Valentina, Mitterbauer-Hohendanner, Gerlinde, Dimovski, Aleksandar, Brieghel, Christian, Lawless, Sarah, Meggendorfer, Manja, Brazdilova, Kamila, Ritgen, Matthias, Facco, Monica, Tresoldi, Cristina, Visentin, Andrea, Patriarca, Andrea, Catherwood, Mark, Bonello, Lisa, Sudarikov, Andrey, Vanura, Katrina, Roumelioti, Maria, Francova, Hana Skuhrova, Moysiadis, Theodoros, Veronese, Silvio, Giannopoulos, Krzysztof, Mansouri, Larry, Karan-Đurašević, Teodora, Sandaltzopoulos, Raphael, Bodor, Csaba, Fais, Franco, Kater, Arnon, Panovska, Irina, Rossi, Davide, Alshemmari, Salem, Panagiotidis, Panagiotis, Costeas, Paul, Espinet, Blanca, Antić, Darko, Foroni, Letizia, Montillo, Marco, Trentin, Livio, Stavroyianni, Niki, Gaidano, Gianluca, di Celle, Paola Francia, Niemann, Carsten, Campo, Elias, Anagnostopoulos, Achilles, Pott, Christiane, Fischer, Kirsten, Hallek, Michael, Oscier, David, Stilgenbauer, Stephan, Haferlach, Claudia, Jelinek, Diane, Chiorazzi, Nicholas, Pospisilova, Sarka, Lefranc, Marie-Paule, Kossida, Sofia, Langerak, Anton W., Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, "Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL" in Blood, 137, no. 10 (2021):1365-1376,
https://doi.org/10.1182/blood.2020007039 . .

TY  - JOUR
AU  - Vuković, Vojin
AU  - Karan-Đurašević, Teodora
AU  - Antić, Darko
AU  - Tošić, Nataša
AU  - Kostić, Tatjana
AU  - Marjanović, Irena
AU  - Denčić-Fekete, Marija
AU  - Đurašinović, Vladislava
AU  - Pavlović, Sonja
AU  - Mihaljević, Biljana
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1321
AB  - Fludarabine plus cyclophosphamide (FC) chemotherapy is the basis of treatment protocols used in management of chronic lymphocytic leukemia (CLL). In some patients, response to therapy may be affected by aberrant function of genes involved in pharmacokinetics and pharmacodynamics of the drugs. The aim of this research was to assess the impact of pharmacogenetic variability, namely expression of SLC28A3 gene and the presence of CYP2B6*6 variant allele, on the FC treatment efficacy. Forty-four CLL patients with functional TP53 gene at the time of FC initiation were enrolled in this study. CYP2B6 genotyping was performed by polymerase chain reaction and direct sequencing. SLC28A3 expression was measured by quantitative reverse-transcriptase polymerase chain reaction. Significantly higher pretreatment levels of SLC28A3 mRNA were detected in patients who failed to respond to FC in comparison to patients who achieved complete and partial response (p = 0.01). SLC28A3 high-expressing cases were almost ten times more likely not to respond to FC than low-expressing cases (OR = 9.8; p = 0.046). However, association of SLC28A3 expression with progression-free survival (PFS) and overall survival (OS) was not observed. CYP2B6*6 allele, detected in 24 patients (54.6%), exerted no association with the attainment of response to FC, as well as with PFS and OS. The results of this study demonstrate that SLC28A3 expression is a significant predictor of FC efficacy in CLL patients with intact TP53. Elevated SLC28A3 mRNA levels are associated with inferior short-term response to FC, suggesting that, if validated on larger cohorts, SLC28A3 expression may become a biomarker useful for pretreatment stratification of patients.
PB  - Frontiers Media Sa, Lausanne
T2  - Pathology & Oncology Research
T1  - Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients
EP  - 752
IS  - 2
SP  - 743
VL  - 26
DO  - 10.1007/s12253-019-00613-4
ER  - 

@article{
author = "Vuković, Vojin and Karan-Đurašević, Teodora and Antić, Darko and Tošić, Nataša and Kostić, Tatjana and Marjanović, Irena and Denčić-Fekete, Marija and Đurašinović, Vladislava and Pavlović, Sonja and Mihaljević, Biljana",
year = "2020",
abstract = "Fludarabine plus cyclophosphamide (FC) chemotherapy is the basis of treatment protocols used in management of chronic lymphocytic leukemia (CLL). In some patients, response to therapy may be affected by aberrant function of genes involved in pharmacokinetics and pharmacodynamics of the drugs. The aim of this research was to assess the impact of pharmacogenetic variability, namely expression of SLC28A3 gene and the presence of CYP2B6*6 variant allele, on the FC treatment efficacy. Forty-four CLL patients with functional TP53 gene at the time of FC initiation were enrolled in this study. CYP2B6 genotyping was performed by polymerase chain reaction and direct sequencing. SLC28A3 expression was measured by quantitative reverse-transcriptase polymerase chain reaction. Significantly higher pretreatment levels of SLC28A3 mRNA were detected in patients who failed to respond to FC in comparison to patients who achieved complete and partial response (p = 0.01). SLC28A3 high-expressing cases were almost ten times more likely not to respond to FC than low-expressing cases (OR = 9.8; p = 0.046). However, association of SLC28A3 expression with progression-free survival (PFS) and overall survival (OS) was not observed. CYP2B6*6 allele, detected in 24 patients (54.6%), exerted no association with the attainment of response to FC, as well as with PFS and OS. The results of this study demonstrate that SLC28A3 expression is a significant predictor of FC efficacy in CLL patients with intact TP53. Elevated SLC28A3 mRNA levels are associated with inferior short-term response to FC, suggesting that, if validated on larger cohorts, SLC28A3 expression may become a biomarker useful for pretreatment stratification of patients.",
publisher = "Frontiers Media Sa, Lausanne",
journal = "Pathology & Oncology Research",
title = "Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients",
pages = "752-743",
number = "2",
volume = "26",
doi = "10.1007/s12253-019-00613-4"
}

Vuković, V., Karan-Đurašević, T., Antić, D., Tošić, N., Kostić, T., Marjanović, I., Denčić-Fekete, M., Đurašinović, V., Pavlović, S.,& Mihaljević, B.. (2020). Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients. in Pathology & Oncology Research
Frontiers Media Sa, Lausanne., 26(2), 743-752.
https://doi.org/10.1007/s12253-019-00613-4

Vuković V, Karan-Đurašević T, Antić D, Tošić N, Kostić T, Marjanović I, Denčić-Fekete M, Đurašinović V, Pavlović S, Mihaljević B. Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients. in Pathology & Oncology Research. 2020;26(2):743-752.
doi:10.1007/s12253-019-00613-4 .

Vuković, Vojin, Karan-Đurašević, Teodora, Antić, Darko, Tošić, Nataša, Kostić, Tatjana, Marjanović, Irena, Denčić-Fekete, Marija, Đurašinović, Vladislava, Pavlović, Sonja, Mihaljević, Biljana, "Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients" in Pathology & Oncology Research, 26, no. 2 (2020):743-752,
https://doi.org/10.1007/s12253-019-00613-4 . .

TY  - JOUR
AU  - Tomić, Kristina
AU  - Karan-Đurašević, Teodora
AU  - Vuković, Vojin
AU  - Mihaljević, Biljana
AU  - Antić, Darko
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1346
AB  - Hronična limfocitna leukemija (HLL) izuzetno je heterogena bolest varijabilnog kliničkog toka. S jedne strane imamo, pacijente sa agresivnom i rezistentnom bolešću od koje umiru svega par meseci nakon dijagnoze, dok s druge strane spektra postoje pacijenti sa indolentnom, sporo progredirajućom bolešću koja ne zahteva lečenje decenijama. Razlozi su samo delimično poznati i već su decenijama unazad tema mnogobrojnih naučnih istraživanja. Tako je razvijen koncept prognostičkih i prediktivnih faktora u HLL-u, koji imaju za cilj da predvide klinički tok, odnosno terapijski ishod HLL-a. Liste prognostičkih i prediktivnih faktora su, sa boljim poznavanjem patofiziologije ove bolesti, svakom godinom sve duže, ali se i međusobno preklapaju. U ovom revijalnom radu izabrali smo aberacije TP53 gena i mutacioni status rearanžiranih IGHV (engl. immunoglobulin heavy variable) gena kao dva najznačajnija i najproučavanija faktora koji imaju i prognostički i prediktivni značaj.
AB  - Chronic lymphocytic leukemia (CLL) is a very heterogeneous disease with a variable clinical course. On the one side of the spectrum, there are patients with aggressive and resistant disease, of which they die only a few months after diagnosis while, on the other side, there are patients with an indolent, slowly progressive disease that does not require treatment for decades. The reasons for this are only partially known, but they have been the subject of numerous scientific studies during the last several decades. Consequently, the concept of prognostic and predictive factors in CLL have emerged, which aims to predict the clinical course and its therapeutic outcome. With the improvement of understanding the pathophysiology of this disease, the lists of prognostic and predictive factors are getting longer every year, but they also overlap. In this review, we singled out the aberrations of the TP53 gene and the IGHV (immunoglobulin heavy variable) gene mutational status as the two most important and most studied factors that have both prognostic and predictive significance.
PB  - Univerzitet u Beogradu - Medicinski fakultet, Beograd
T2  - Medicinski podmladak
T1  - Klinički značaj aberacija TP53 gena i IGHV mutacionog statusa u hroničnoj limfocitnoj leukemiji
T1  - Clinical significance of TP53 aberrations and IGHV mutational status in chronic lymphocytic leukemia
EP  - 53
IS  - 4
SP  - 47
VL  - 71
DO  - 10.5937/mp71-28969
ER  - 

@article{
author = "Tomić, Kristina and Karan-Đurašević, Teodora and Vuković, Vojin and Mihaljević, Biljana and Antić, Darko",
year = "2020",
abstract = "Hronična limfocitna leukemija (HLL) izuzetno je heterogena bolest varijabilnog kliničkog toka. S jedne strane imamo, pacijente sa agresivnom i rezistentnom bolešću od koje umiru svega par meseci nakon dijagnoze, dok s druge strane spektra postoje pacijenti sa indolentnom, sporo progredirajućom bolešću koja ne zahteva lečenje decenijama. Razlozi su samo delimično poznati i već su decenijama unazad tema mnogobrojnih naučnih istraživanja. Tako je razvijen koncept prognostičkih i prediktivnih faktora u HLL-u, koji imaju za cilj da predvide klinički tok, odnosno terapijski ishod HLL-a. Liste prognostičkih i prediktivnih faktora su, sa boljim poznavanjem patofiziologije ove bolesti, svakom godinom sve duže, ali se i međusobno preklapaju. U ovom revijalnom radu izabrali smo aberacije TP53 gena i mutacioni status rearanžiranih IGHV (engl. immunoglobulin heavy variable) gena kao dva najznačajnija i najproučavanija faktora koji imaju i prognostički i prediktivni značaj., Chronic lymphocytic leukemia (CLL) is a very heterogeneous disease with a variable clinical course. On the one side of the spectrum, there are patients with aggressive and resistant disease, of which they die only a few months after diagnosis while, on the other side, there are patients with an indolent, slowly progressive disease that does not require treatment for decades. The reasons for this are only partially known, but they have been the subject of numerous scientific studies during the last several decades. Consequently, the concept of prognostic and predictive factors in CLL have emerged, which aims to predict the clinical course and its therapeutic outcome. With the improvement of understanding the pathophysiology of this disease, the lists of prognostic and predictive factors are getting longer every year, but they also overlap. In this review, we singled out the aberrations of the TP53 gene and the IGHV (immunoglobulin heavy variable) gene mutational status as the two most important and most studied factors that have both prognostic and predictive significance.",
publisher = "Univerzitet u Beogradu - Medicinski fakultet, Beograd",
journal = "Medicinski podmladak",
title = "Klinički značaj aberacija TP53 gena i IGHV mutacionog statusa u hroničnoj limfocitnoj leukemiji, Clinical significance of TP53 aberrations and IGHV mutational status in chronic lymphocytic leukemia",
pages = "53-47",
number = "4",
volume = "71",
doi = "10.5937/mp71-28969"
}

Tomić, K., Karan-Đurašević, T., Vuković, V., Mihaljević, B.,& Antić, D.. (2020). Klinički značaj aberacija TP53 gena i IGHV mutacionog statusa u hroničnoj limfocitnoj leukemiji. in Medicinski podmladak
Univerzitet u Beogradu - Medicinski fakultet, Beograd., 71(4), 47-53.
https://doi.org/10.5937/mp71-28969

Tomić K, Karan-Đurašević T, Vuković V, Mihaljević B, Antić D. Klinički značaj aberacija TP53 gena i IGHV mutacionog statusa u hroničnoj limfocitnoj leukemiji. in Medicinski podmladak. 2020;71(4):47-53.
doi:10.5937/mp71-28969 .

Tomić, Kristina, Karan-Đurašević, Teodora, Vuković, Vojin, Mihaljević, Biljana, Antić, Darko, "Klinički značaj aberacija TP53 gena i IGHV mutacionog statusa u hroničnoj limfocitnoj leukemiji" in Medicinski podmladak, 71, no. 4 (2020):47-53,
https://doi.org/10.5937/mp71-28969 . .

TY  - CONF
AU  - Gvozdenov, Maja
AU  - Pruner, Iva
AU  - Tomić, Branko
AU  - Kovač, Mirjana
AU  - Miljić, Predrag
AU  - Antić, Darko
AU  - Đorđević, Valentina
AU  - Radojković, Dragica
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1136
PB  - Nature Publishing Group, London
C3  - European Journal of Human Genetics
T1  - Functional analyses of the FIIc.*64_*66del gene variant and its potential role in fetal loss etiology
EP  - 828
SP  - 827
VL  - 26
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1136
ER  - 

@conference{
author = "Gvozdenov, Maja and Pruner, Iva and Tomić, Branko and Kovač, Mirjana and Miljić, Predrag and Antić, Darko and Đorđević, Valentina and Radojković, Dragica",
year = "2018",
publisher = "Nature Publishing Group, London",
journal = "European Journal of Human Genetics",
title = "Functional analyses of the FIIc.*64_*66del gene variant and its potential role in fetal loss etiology",
pages = "828-827",
volume = "26",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1136"
}

Gvozdenov, M., Pruner, I., Tomić, B., Kovač, M., Miljić, P., Antić, D., Đorđević, V.,& Radojković, D.. (2018). Functional analyses of the FIIc.*64_*66del gene variant and its potential role in fetal loss etiology. in European Journal of Human Genetics
Nature Publishing Group, London., 26, 827-828.
https://hdl.handle.net/21.15107/rcub_imagine_1136

Gvozdenov M, Pruner I, Tomić B, Kovač M, Miljić P, Antić D, Đorđević V, Radojković D. Functional analyses of the FIIc.*64_*66del gene variant and its potential role in fetal loss etiology. in European Journal of Human Genetics. 2018;26:827-828.
https://hdl.handle.net/21.15107/rcub_imagine_1136 .

Gvozdenov, Maja, Pruner, Iva, Tomić, Branko, Kovač, Mirjana, Miljić, Predrag, Antić, Darko, Đorđević, Valentina, Radojković, Dragica, "Functional analyses of the FIIc.*64_*66del gene variant and its potential role in fetal loss etiology" in European Journal of Human Genetics, 26 (2018):827-828,
https://hdl.handle.net/21.15107/rcub_imagine_1136 .

TY  - JOUR
AU  - Xochelli, Aliki
AU  - Baliakas, Panagiotis
AU  - Kavakiotis, Ioannis
AU  - Agathangelidis, Andreas
AU  - Sutton, Lesley-Ann
AU  - Minga, Eva
AU  - Ntoufa, Stavroula
AU  - Tausch, Eugen
AU  - Yan, Xiao-Jie
AU  - Shanafelt, Tait
AU  - Plevova, Karla
AU  - Boudjogra, Myriam
AU  - Rossi, Davide
AU  - Davis, Zadie
AU  - Navarro, Alba
AU  - Sandberg, Yorick
AU  - Vojdeman, Fie Juhl
AU  - Scarfo, Lydia
AU  - Stavroyianni, Niki
AU  - Sudarikov, Andrey
AU  - Veronese, Silvio
AU  - Tzenou, Tatiana
AU  - Karan-Đurašević, Teodora
AU  - Catherwood, Mark
AU  - Kienle, Dirk
AU  - Chatzouli, Maria
AU  - Facco, Monica
AU  - Bahlo, Jasmin
AU  - Pott, Christiane
AU  - Pedersen, Lone Bredo
AU  - Mansouri, Larry
AU  - Smedby, Karin E.
AU  - Chu, Charles C.
AU  - Giudicelli, Veronique
AU  - Lefranc, Marie-Paule
AU  - Panagiotidis, Panagiotis
AU  - Juliusson, Gunnar
AU  - Anagnostopoulos, Achilles
AU  - Vlahavas, Ioannis
AU  - Antić, Darko
AU  - Trentin, Livio
AU  - Montillo, Marco
AU  - Niemann, Carsten
AU  - Doehner, Hartmut
AU  - Langerak, Anton W.
AU  - Pospisilova, Sarka
AU  - Hallek, Michael
AU  - Campo, Elias
AU  - Chiorazzi, Nicholas
AU  - Maglaveras, Nikos
AU  - Oscier, David
AU  - Gaidano, Gianluca
AU  - Jelinek, Diane F.
AU  - Stilgenbauer, Stephan
AU  - Chouvarda, Ioanna
AU  - Darzentas, Nikos
AU  - Belessi, Chrysoula
AU  - Davi, Frederic
AU  - Hadzidimitriou, Anastasia
AU  - Rosenquist, Richard
AU  - Ghia, Paolo
AU  - Stamatopoulos, Kostas
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1611
AB  - Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P  lt  0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management.
PB  - Amer Assoc Cancer Research, Philadelphia
T2  - Clinical Cancer Research
T1  - Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
EP  - 5301
IS  - 17
SP  - 5292
VL  - 23
DO  - 10.1158/1078-0432.CCR-16-3100
ER  - 

@article{
author = "Xochelli, Aliki and Baliakas, Panagiotis and Kavakiotis, Ioannis and Agathangelidis, Andreas and Sutton, Lesley-Ann and Minga, Eva and Ntoufa, Stavroula and Tausch, Eugen and Yan, Xiao-Jie and Shanafelt, Tait and Plevova, Karla and Boudjogra, Myriam and Rossi, Davide and Davis, Zadie and Navarro, Alba and Sandberg, Yorick and Vojdeman, Fie Juhl and Scarfo, Lydia and Stavroyianni, Niki and Sudarikov, Andrey and Veronese, Silvio and Tzenou, Tatiana and Karan-Đurašević, Teodora and Catherwood, Mark and Kienle, Dirk and Chatzouli, Maria and Facco, Monica and Bahlo, Jasmin and Pott, Christiane and Pedersen, Lone Bredo and Mansouri, Larry and Smedby, Karin E. and Chu, Charles C. and Giudicelli, Veronique and Lefranc, Marie-Paule and Panagiotidis, Panagiotis and Juliusson, Gunnar and Anagnostopoulos, Achilles and Vlahavas, Ioannis and Antić, Darko and Trentin, Livio and Montillo, Marco and Niemann, Carsten and Doehner, Hartmut and Langerak, Anton W. and Pospisilova, Sarka and Hallek, Michael and Campo, Elias and Chiorazzi, Nicholas and Maglaveras, Nikos and Oscier, David and Gaidano, Gianluca and Jelinek, Diane F. and Stilgenbauer, Stephan and Chouvarda, Ioanna and Darzentas, Nikos and Belessi, Chrysoula and Davi, Frederic and Hadzidimitriou, Anastasia and Rosenquist, Richard and Ghia, Paolo and Stamatopoulos, Kostas",
year = "2017",
abstract = "Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P  lt  0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management.",
publisher = "Amer Assoc Cancer Research, Philadelphia",
journal = "Clinical Cancer Research",
title = "Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes",
pages = "5301-5292",
number = "17",
volume = "23",
doi = "10.1158/1078-0432.CCR-16-3100"
}

Xochelli, A., Baliakas, P., Kavakiotis, I., Agathangelidis, A., Sutton, L., Minga, E., Ntoufa, S., Tausch, E., Yan, X., Shanafelt, T., Plevova, K., Boudjogra, M., Rossi, D., Davis, Z., Navarro, A., Sandberg, Y., Vojdeman, F. J., Scarfo, L., Stavroyianni, N., Sudarikov, A., Veronese, S., Tzenou, T., Karan-Đurašević, T., Catherwood, M., Kienle, D., Chatzouli, M., Facco, M., Bahlo, J., Pott, C., Pedersen, L. B., Mansouri, L., Smedby, K. E., Chu, C. C., Giudicelli, V., Lefranc, M., Panagiotidis, P., Juliusson, G., Anagnostopoulos, A., Vlahavas, I., Antić, D., Trentin, L., Montillo, M., Niemann, C., Doehner, H., Langerak, A. W., Pospisilova, S., Hallek, M., Campo, E., Chiorazzi, N., Maglaveras, N., Oscier, D., Gaidano, G., Jelinek, D. F., Stilgenbauer, S., Chouvarda, I., Darzentas, N., Belessi, C., Davi, F., Hadzidimitriou, A., Rosenquist, R., Ghia, P.,& Stamatopoulos, K.. (2017). Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. in Clinical Cancer Research
Amer Assoc Cancer Research, Philadelphia., 23(17), 5292-5301.
https://doi.org/10.1158/1078-0432.CCR-16-3100

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton L, Minga E, Ntoufa S, Tausch E, Yan X, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Đurašević T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc M, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antić D, Trentin L, Montillo M, Niemann C, Doehner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. in Clinical Cancer Research. 2017;23(17):5292-5301.
doi:10.1158/1078-0432.CCR-16-3100 .

Xochelli, Aliki, Baliakas, Panagiotis, Kavakiotis, Ioannis, Agathangelidis, Andreas, Sutton, Lesley-Ann, Minga, Eva, Ntoufa, Stavroula, Tausch, Eugen, Yan, Xiao-Jie, Shanafelt, Tait, Plevova, Karla, Boudjogra, Myriam, Rossi, Davide, Davis, Zadie, Navarro, Alba, Sandberg, Yorick, Vojdeman, Fie Juhl, Scarfo, Lydia, Stavroyianni, Niki, Sudarikov, Andrey, Veronese, Silvio, Tzenou, Tatiana, Karan-Đurašević, Teodora, Catherwood, Mark, Kienle, Dirk, Chatzouli, Maria, Facco, Monica, Bahlo, Jasmin, Pott, Christiane, Pedersen, Lone Bredo, Mansouri, Larry, Smedby, Karin E., Chu, Charles C., Giudicelli, Veronique, Lefranc, Marie-Paule, Panagiotidis, Panagiotis, Juliusson, Gunnar, Anagnostopoulos, Achilles, Vlahavas, Ioannis, Antić, Darko, Trentin, Livio, Montillo, Marco, Niemann, Carsten, Doehner, Hartmut, Langerak, Anton W., Pospisilova, Sarka, Hallek, Michael, Campo, Elias, Chiorazzi, Nicholas, Maglaveras, Nikos, Oscier, David, Gaidano, Gianluca, Jelinek, Diane F., Stilgenbauer, Stephan, Chouvarda, Ioanna, Darzentas, Nikos, Belessi, Chrysoula, Davi, Frederic, Hadzidimitriou, Anastasia, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, "Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes" in Clinical Cancer Research, 23, no. 17 (2017):5292-5301,
https://doi.org/10.1158/1078-0432.CCR-16-3100 . .

TY  - JOUR
AU  - Xochelli, Aliki
AU  - Baliakas, Panagiotis
AU  - Kavakiotis, Ioannis
AU  - Agathangelidis, Andreas
AU  - Sutton, Lesley-Ann
AU  - Minga, Eva
AU  - Ntoufa, Stavroula
AU  - Tausch, Eugen
AU  - Yan, Xiao-Jie
AU  - Shanafelt, Tait
AU  - Plevova, Karla
AU  - Boudjogra, Myriam
AU  - Rossi, Davide
AU  - Davis, Zadie
AU  - Navarro, Alba
AU  - Sandberg, Yorick
AU  - Vojdeman, Fie Juhl
AU  - Scarfo, Lydia
AU  - Stavroyianni, Niki
AU  - Sudarikov, Andrey
AU  - Veronese, Silvio
AU  - Tzenou, Tatiana
AU  - Karan-Đurašević, Teodora
AU  - Catherwood, Mark
AU  - Kienle, Dirk
AU  - Chatzouli, Maria
AU  - Facco, Monica
AU  - Bahlo, Jasmin
AU  - Pott, Christiane
AU  - Pedersen, Lone Bredo
AU  - Mansouri, Larry
AU  - Smedby, Karin E.
AU  - Chu, Charles C.
AU  - Giudicelli, Veronique
AU  - Lefranc, Marie-Paule
AU  - Panagiotidis, Panagiotis
AU  - Juliusson, Gunnar
AU  - Anagnostopoulos, Achilles
AU  - Vlahavas, Ioannis
AU  - Antić, Darko
AU  - Trentin, Livio
AU  - Montillo, Marco
AU  - Niemann, Carsten
AU  - Doehner, Hartmut
AU  - Langerak, Anton W.
AU  - Pospisilova, Sarka
AU  - Hallek, Michael
AU  - Campo, Elias
AU  - Chiorazzi, Nicholas
AU  - Maglaveras, Nikos
AU  - Oscier, David
AU  - Gaidano, Gianluca
AU  - Jelinek, Diane F.
AU  - Stilgenbauer, Stephan
AU  - Chouvarda, Ioanna
AU  - Darzentas, Nikos
AU  - Belessi, Chrysoula
AU  - Davi, Frederic
AU  - Hadzidimitriou, Anastasia
AU  - Rosenquist, Richard
AU  - Ghia, Paolo
AU  - Stamatopoulos, Kostas
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1017
AB  - Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P  lt  0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management.
PB  - Amer Assoc Cancer Research, Philadelphia
T2  - Clinical Cancer Research
T1  - Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
EP  - 5301
IS  - 17
SP  - 5292
VL  - 23
DO  - 10.1158/1078-0432.CCR-16-3100
ER  - 

@article{
author = "Xochelli, Aliki and Baliakas, Panagiotis and Kavakiotis, Ioannis and Agathangelidis, Andreas and Sutton, Lesley-Ann and Minga, Eva and Ntoufa, Stavroula and Tausch, Eugen and Yan, Xiao-Jie and Shanafelt, Tait and Plevova, Karla and Boudjogra, Myriam and Rossi, Davide and Davis, Zadie and Navarro, Alba and Sandberg, Yorick and Vojdeman, Fie Juhl and Scarfo, Lydia and Stavroyianni, Niki and Sudarikov, Andrey and Veronese, Silvio and Tzenou, Tatiana and Karan-Đurašević, Teodora and Catherwood, Mark and Kienle, Dirk and Chatzouli, Maria and Facco, Monica and Bahlo, Jasmin and Pott, Christiane and Pedersen, Lone Bredo and Mansouri, Larry and Smedby, Karin E. and Chu, Charles C. and Giudicelli, Veronique and Lefranc, Marie-Paule and Panagiotidis, Panagiotis and Juliusson, Gunnar and Anagnostopoulos, Achilles and Vlahavas, Ioannis and Antić, Darko and Trentin, Livio and Montillo, Marco and Niemann, Carsten and Doehner, Hartmut and Langerak, Anton W. and Pospisilova, Sarka and Hallek, Michael and Campo, Elias and Chiorazzi, Nicholas and Maglaveras, Nikos and Oscier, David and Gaidano, Gianluca and Jelinek, Diane F. and Stilgenbauer, Stephan and Chouvarda, Ioanna and Darzentas, Nikos and Belessi, Chrysoula and Davi, Frederic and Hadzidimitriou, Anastasia and Rosenquist, Richard and Ghia, Paolo and Stamatopoulos, Kostas",
year = "2017",
abstract = "Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P  lt  0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management.",
publisher = "Amer Assoc Cancer Research, Philadelphia",
journal = "Clinical Cancer Research",
title = "Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes",
pages = "5301-5292",
number = "17",
volume = "23",
doi = "10.1158/1078-0432.CCR-16-3100"
}

Xochelli, A., Baliakas, P., Kavakiotis, I., Agathangelidis, A., Sutton, L., Minga, E., Ntoufa, S., Tausch, E., Yan, X., Shanafelt, T., Plevova, K., Boudjogra, M., Rossi, D., Davis, Z., Navarro, A., Sandberg, Y., Vojdeman, F. J., Scarfo, L., Stavroyianni, N., Sudarikov, A., Veronese, S., Tzenou, T., Karan-Đurašević, T., Catherwood, M., Kienle, D., Chatzouli, M., Facco, M., Bahlo, J., Pott, C., Pedersen, L. B., Mansouri, L., Smedby, K. E., Chu, C. C., Giudicelli, V., Lefranc, M., Panagiotidis, P., Juliusson, G., Anagnostopoulos, A., Vlahavas, I., Antić, D., Trentin, L., Montillo, M., Niemann, C., Doehner, H., Langerak, A. W., Pospisilova, S., Hallek, M., Campo, E., Chiorazzi, N., Maglaveras, N., Oscier, D., Gaidano, G., Jelinek, D. F., Stilgenbauer, S., Chouvarda, I., Darzentas, N., Belessi, C., Davi, F., Hadzidimitriou, A., Rosenquist, R., Ghia, P.,& Stamatopoulos, K.. (2017). Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. in Clinical Cancer Research
Amer Assoc Cancer Research, Philadelphia., 23(17), 5292-5301.
https://doi.org/10.1158/1078-0432.CCR-16-3100

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton L, Minga E, Ntoufa S, Tausch E, Yan X, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Đurašević T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc M, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antić D, Trentin L, Montillo M, Niemann C, Doehner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. in Clinical Cancer Research. 2017;23(17):5292-5301.
doi:10.1158/1078-0432.CCR-16-3100 .

Xochelli, Aliki, Baliakas, Panagiotis, Kavakiotis, Ioannis, Agathangelidis, Andreas, Sutton, Lesley-Ann, Minga, Eva, Ntoufa, Stavroula, Tausch, Eugen, Yan, Xiao-Jie, Shanafelt, Tait, Plevova, Karla, Boudjogra, Myriam, Rossi, Davide, Davis, Zadie, Navarro, Alba, Sandberg, Yorick, Vojdeman, Fie Juhl, Scarfo, Lydia, Stavroyianni, Niki, Sudarikov, Andrey, Veronese, Silvio, Tzenou, Tatiana, Karan-Đurašević, Teodora, Catherwood, Mark, Kienle, Dirk, Chatzouli, Maria, Facco, Monica, Bahlo, Jasmin, Pott, Christiane, Pedersen, Lone Bredo, Mansouri, Larry, Smedby, Karin E., Chu, Charles C., Giudicelli, Veronique, Lefranc, Marie-Paule, Panagiotidis, Panagiotis, Juliusson, Gunnar, Anagnostopoulos, Achilles, Vlahavas, Ioannis, Antić, Darko, Trentin, Livio, Montillo, Marco, Niemann, Carsten, Doehner, Hartmut, Langerak, Anton W., Pospisilova, Sarka, Hallek, Michael, Campo, Elias, Chiorazzi, Nicholas, Maglaveras, Nikos, Oscier, David, Gaidano, Gianluca, Jelinek, Diane F., Stilgenbauer, Stephan, Chouvarda, Ioanna, Darzentas, Nikos, Belessi, Chrysoula, Davi, Frederic, Hadzidimitriou, Anastasia, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, "Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes" in Clinical Cancer Research, 23, no. 17 (2017):5292-5301,
https://doi.org/10.1158/1078-0432.CCR-16-3100 . .

TY  - CONF
AU  - Vuković, V.
AU  - Antić, Darko
AU  - Karan-Đurašević, Teodora
AU  - Milić, N.
AU  - Todorovic-Balint, M.
AU  - Bila, J.
AU  - Anđelić, Boško
AU  - Đurašinović, Vladislava
AU  - Sretenović, A.
AU  - Smiljanić, M.
AU  - Jelicić, J.
AU  - Denčić-Fekete, Marija
AU  - Perunicić-Jovanović, M.
AU  - Kraguljac-Kurtović, N.
AU  - Pavlović, Sonja
AU  - Mihaljević, B.
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1075
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution
EP  - 719
SP  - 719
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1075
ER  - 

@conference{
author = "Vuković, V. and Antić, Darko and Karan-Đurašević, Teodora and Milić, N. and Todorovic-Balint, M. and Bila, J. and Anđelić, Boško and Đurašinović, Vladislava and Sretenović, A. and Smiljanić, M. and Jelicić, J. and Denčić-Fekete, Marija and Perunicić-Jovanović, M. and Kraguljac-Kurtović, N. and Pavlović, Sonja and Mihaljević, B.",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution",
pages = "719-719",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1075"
}

Vuković, V., Antić, D., Karan-Đurašević, T., Milić, N., Todorovic-Balint, M., Bila, J., Anđelić, B., Đurašinović, V., Sretenović, A., Smiljanić, M., Jelicić, J., Denčić-Fekete, M., Perunicić-Jovanović, M., Kraguljac-Kurtović, N., Pavlović, S.,& Mihaljević, B.. (2017). Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 102, 719-719.
https://hdl.handle.net/21.15107/rcub_imagine_1075

Vuković V, Antić D, Karan-Đurašević T, Milić N, Todorovic-Balint M, Bila J, Anđelić B, Đurašinović V, Sretenović A, Smiljanić M, Jelicić J, Denčić-Fekete M, Perunicić-Jovanović M, Kraguljac-Kurtović N, Pavlović S, Mihaljević B. Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution. in Haematologica-The Hematology Journal. 2017;102:719-719.
https://hdl.handle.net/21.15107/rcub_imagine_1075 .

Vuković, V., Antić, Darko, Karan-Đurašević, Teodora, Milić, N., Todorovic-Balint, M., Bila, J., Anđelić, Boško, Đurašinović, Vladislava, Sretenović, A., Smiljanić, M., Jelicić, J., Denčić-Fekete, Marija, Perunicić-Jovanović, M., Kraguljac-Kurtović, N., Pavlović, Sonja, Mihaljević, B., "Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution" in Haematologica-The Hematology Journal, 102 (2017):719-719,
https://hdl.handle.net/21.15107/rcub_imagine_1075 .

TY  - CONF
AU  - Vuković, V.
AU  - Antić, Darko
AU  - Karan-Đurašević, Teodora
AU  - Milić, N.
AU  - Todorovic-Balint, M.
AU  - Bila, J.
AU  - Anđelić, Boško
AU  - Đurašinović, Vladislava
AU  - Sretenović, A.
AU  - Smiljanić, M.
AU  - Jelicić, J.
AU  - Denčić-Fekete, Marija
AU  - Perunicić-Jovanović, M.
AU  - Kraguljac-Kurtović, N.
AU  - Pavlović, Sonja
AU  - Mihaljević, B.
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1070
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia
EP  - 711
SP  - 710
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1070
ER  - 

@conference{
author = "Vuković, V. and Antić, Darko and Karan-Đurašević, Teodora and Milić, N. and Todorovic-Balint, M. and Bila, J. and Anđelić, Boško and Đurašinović, Vladislava and Sretenović, A. and Smiljanić, M. and Jelicić, J. and Denčić-Fekete, Marija and Perunicić-Jovanović, M. and Kraguljac-Kurtović, N. and Pavlović, Sonja and Mihaljević, B.",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia",
pages = "711-710",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1070"
}

Vuković, V., Antić, D., Karan-Đurašević, T., Milić, N., Todorovic-Balint, M., Bila, J., Anđelić, B., Đurašinović, V., Sretenović, A., Smiljanić, M., Jelicić, J., Denčić-Fekete, M., Perunicić-Jovanović, M., Kraguljac-Kurtović, N., Pavlović, S.,& Mihaljević, B.. (2017). Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 102, 710-711.
https://hdl.handle.net/21.15107/rcub_imagine_1070

Vuković V, Antić D, Karan-Đurašević T, Milić N, Todorovic-Balint M, Bila J, Anđelić B, Đurašinović V, Sretenović A, Smiljanić M, Jelicić J, Denčić-Fekete M, Perunicić-Jovanović M, Kraguljac-Kurtović N, Pavlović S, Mihaljević B. Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia. in Haematologica-The Hematology Journal. 2017;102:710-711.
https://hdl.handle.net/21.15107/rcub_imagine_1070 .

Vuković, V., Antić, Darko, Karan-Đurašević, Teodora, Milić, N., Todorovic-Balint, M., Bila, J., Anđelić, Boško, Đurašinović, Vladislava, Sretenović, A., Smiljanić, M., Jelicić, J., Denčić-Fekete, Marija, Perunicić-Jovanović, M., Kraguljac-Kurtović, N., Pavlović, Sonja, Mihaljević, B., "Overexpression of gene for human concentrative nucleoside transporter 3 is a predictor of resistance to fludarabin-based chemotherapy in patients with chronic lymphocytic leukemia" in Haematologica-The Hematology Journal, 102 (2017):710-711,
https://hdl.handle.net/21.15107/rcub_imagine_1070 .

TY  - JOUR
AU  - Jelicić, Jelena
AU  - Todorovic-Balint, Milena
AU  - Perunicić-Jovanović, Maja
AU  - Boricić, Novica
AU  - Micev, Marjan
AU  - Stojsić, Jelena
AU  - Antić, Darko
AU  - Anđelić, Boško
AU  - Bila, Jelena
AU  - Balint, Bela
AU  - Pavlović, Sonja
AU  - Mihaljević, Biljana
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/944
AB  - Prognostic significance of immune microenvironment has been emphasized using the most advanced analysis, with consecutive attempts to reveal prognostic impact of this findings. The aim of this study was to compare and define prognostic significance of clinical parameters, microvessel density (MVD) in tumour tissue and expression of CD44s as adhesive molecule on tumour cells in diffuse large B cell lymphoma-DLBCL, primary central nervous system DLBCL-CNS DLBCL and follicular lymphoma-FL. A total of 202 histopathological samples (115 DLBCL/65 FL/22 CNS DLBCL) were evaluated. Overall response (complete/partial remission) was achieved in 81.3 % DLBCL patients, 81.8 % primary CNS DLBCL and 92.3 % FL. Absolute lymphocyte count-ALC/Absolute monocyte count-AMC  gt  2.6 in DLBCL and ALC/AMC a parts per thousand yenaEuro parts per thousand 4.7 in FL were associated with better event-free survival (EFS) and overall survival (OS) (p  lt  0.05). In DLBCL, MVD  gt  42 blood vessels/0.36 mm(2) correlated with primary resistant disease (p  lt  0.0001), poorer EFS and OS (p = 0.014). High CD44s expression in FL correlated with inferior EFS and OS (p  lt  0.01). In DLBCL, multivariate Cox regression analysis showed that ALC/AMC was independent parameter that affected OS (HR 3.27, 95 % CI 1.51-7.09, p = 0.003) along with the NCCN-IPI (HR 1.39, 95 % CI 1.08-1.79, p = 0.01). Furthermore, in FL, ALC/AMC mostly influenced OS (HR 5.21, 95 % CI 1.17-23.21, p = 0.03), followed with the FLIPI (HR 3.98, 95 % CI 1.06-14.95, p = 0.041). In DLBCL and FL, ALC/AMC is simple and robust tool that is, with current prognostic scores, able to define long-term survival and identify patients with inferior outcome. The introduction of immunochemotherapy might altered the prognostic significance of microenvionmental biomarkers (MVD and CD44s).
PB  - Springer, Dordrecht
T2  - Pathology & Oncology Research
T1  - The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas
EP  - 577
IS  - 3
SP  - 567
VL  - 22
DO  - 10.1007/s12253-015-0032-7
ER  - 

@article{
author = "Jelicić, Jelena and Todorovic-Balint, Milena and Perunicić-Jovanović, Maja and Boricić, Novica and Micev, Marjan and Stojsić, Jelena and Antić, Darko and Anđelić, Boško and Bila, Jelena and Balint, Bela and Pavlović, Sonja and Mihaljević, Biljana",
year = "2016",
abstract = "Prognostic significance of immune microenvironment has been emphasized using the most advanced analysis, with consecutive attempts to reveal prognostic impact of this findings. The aim of this study was to compare and define prognostic significance of clinical parameters, microvessel density (MVD) in tumour tissue and expression of CD44s as adhesive molecule on tumour cells in diffuse large B cell lymphoma-DLBCL, primary central nervous system DLBCL-CNS DLBCL and follicular lymphoma-FL. A total of 202 histopathological samples (115 DLBCL/65 FL/22 CNS DLBCL) were evaluated. Overall response (complete/partial remission) was achieved in 81.3 % DLBCL patients, 81.8 % primary CNS DLBCL and 92.3 % FL. Absolute lymphocyte count-ALC/Absolute monocyte count-AMC  gt  2.6 in DLBCL and ALC/AMC a parts per thousand yenaEuro parts per thousand 4.7 in FL were associated with better event-free survival (EFS) and overall survival (OS) (p  lt  0.05). In DLBCL, MVD  gt  42 blood vessels/0.36 mm(2) correlated with primary resistant disease (p  lt  0.0001), poorer EFS and OS (p = 0.014). High CD44s expression in FL correlated with inferior EFS and OS (p  lt  0.01). In DLBCL, multivariate Cox regression analysis showed that ALC/AMC was independent parameter that affected OS (HR 3.27, 95 % CI 1.51-7.09, p = 0.003) along with the NCCN-IPI (HR 1.39, 95 % CI 1.08-1.79, p = 0.01). Furthermore, in FL, ALC/AMC mostly influenced OS (HR 5.21, 95 % CI 1.17-23.21, p = 0.03), followed with the FLIPI (HR 3.98, 95 % CI 1.06-14.95, p = 0.041). In DLBCL and FL, ALC/AMC is simple and robust tool that is, with current prognostic scores, able to define long-term survival and identify patients with inferior outcome. The introduction of immunochemotherapy might altered the prognostic significance of microenvionmental biomarkers (MVD and CD44s).",
publisher = "Springer, Dordrecht",
journal = "Pathology & Oncology Research",
title = "The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas",
pages = "577-567",
number = "3",
volume = "22",
doi = "10.1007/s12253-015-0032-7"
}

Jelicić, J., Todorovic-Balint, M., Perunicić-Jovanović, M., Boricić, N., Micev, M., Stojsić, J., Antić, D., Anđelić, B., Bila, J., Balint, B., Pavlović, S.,& Mihaljević, B.. (2016). The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. in Pathology & Oncology Research
Springer, Dordrecht., 22(3), 567-577.
https://doi.org/10.1007/s12253-015-0032-7

Jelicić J, Todorovic-Balint M, Perunicić-Jovanović M, Boricić N, Micev M, Stojsić J, Antić D, Anđelić B, Bila J, Balint B, Pavlović S, Mihaljević B. The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. in Pathology & Oncology Research. 2016;22(3):567-577.
doi:10.1007/s12253-015-0032-7 .

Jelicić, Jelena, Todorovic-Balint, Milena, Perunicić-Jovanović, Maja, Boricić, Novica, Micev, Marjan, Stojsić, Jelena, Antić, Darko, Anđelić, Boško, Bila, Jelena, Balint, Bela, Pavlović, Sonja, Mihaljević, Biljana, "The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas" in Pathology & Oncology Research, 22, no. 3 (2016):567-577,
https://doi.org/10.1007/s12253-015-0032-7 . .

TY  - JOUR
AU  - Todorovic-Balint, Milena
AU  - Jelicić, Jelena
AU  - Mihaljević, Biljana
AU  - Kostić, Jelena
AU  - Stanić, Bojana
AU  - Balint, Bela
AU  - Pejanović, Nadja
AU  - Lucić, Bojana
AU  - Tošić, Nataša
AU  - Marjanović, Irena
AU  - Stojiljković, Maja
AU  - Karan-Đurašević, Teodora
AU  - Perisić, Ognjen
AU  - Rakocević, Goran
AU  - Popović, Milos
AU  - Raicević, Sava
AU  - Bila, Jelena
AU  - Antić, Darko
AU  - Anđelić, Boško
AU  - Pavlović, Sonja
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/936
AB  - The existence of a potential primary central nervous system lymphoma-specific genomic signature that differs from the systemic form of diffuse large B cell lymphoma (DLBCL) has been suggested, but is still controversial. We investigated 19 patients with primary DLBCL of central nervous system (DLBCL CNS) using the TruSeq Amplicon Cancer Panel (TSACP) for 48 cancer-related genes. Next generation sequencing (NGS) analyses have revealed that over 80% of potentially protein-changing mutations were located in eight genes (CTNNB1, PIK3CA, PTEN, ATM, KRAS, PTPN11, TP53 and JAK3), pointing to the potential role of these genes in lymphomagenesis. TP53 was the only gene harboring mutations in all 19 patients. In addition, the presence of mutated TP53 and ATM genes correlated with a higher total number of mutations in other analyzed genes. Furthermore, the presence of mutated ATM correlated with poorer event-free survival (EFS) (p = 0.036). The presence of the mutated SMO gene correlated with earlier disease relapse (p = 0.023), inferior event-free survival (p = 0.011) and overall survival (OS) (p = 0.017), while mutations in the PTEN gene were associated with inferior OS (p = 0.048). Our findings suggest that the TP53 and ATM genes could be involved in the molecular pathophysiology of primary DLBCL CNS, whereas mutations in the PTEN and SMO genes could affect survival regardless of the initial treatment approach.
PB  - MDPI, Basel
T2  - International Journal of Molecular Sciences
T1  - Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses
IS  - 5
VL  - 17
DO  - 10.3390/ijms17050683
ER  - 

@article{
author = "Todorovic-Balint, Milena and Jelicić, Jelena and Mihaljević, Biljana and Kostić, Jelena and Stanić, Bojana and Balint, Bela and Pejanović, Nadja and Lucić, Bojana and Tošić, Nataša and Marjanović, Irena and Stojiljković, Maja and Karan-Đurašević, Teodora and Perisić, Ognjen and Rakocević, Goran and Popović, Milos and Raicević, Sava and Bila, Jelena and Antić, Darko and Anđelić, Boško and Pavlović, Sonja",
year = "2016",
abstract = "The existence of a potential primary central nervous system lymphoma-specific genomic signature that differs from the systemic form of diffuse large B cell lymphoma (DLBCL) has been suggested, but is still controversial. We investigated 19 patients with primary DLBCL of central nervous system (DLBCL CNS) using the TruSeq Amplicon Cancer Panel (TSACP) for 48 cancer-related genes. Next generation sequencing (NGS) analyses have revealed that over 80% of potentially protein-changing mutations were located in eight genes (CTNNB1, PIK3CA, PTEN, ATM, KRAS, PTPN11, TP53 and JAK3), pointing to the potential role of these genes in lymphomagenesis. TP53 was the only gene harboring mutations in all 19 patients. In addition, the presence of mutated TP53 and ATM genes correlated with a higher total number of mutations in other analyzed genes. Furthermore, the presence of mutated ATM correlated with poorer event-free survival (EFS) (p = 0.036). The presence of the mutated SMO gene correlated with earlier disease relapse (p = 0.023), inferior event-free survival (p = 0.011) and overall survival (OS) (p = 0.017), while mutations in the PTEN gene were associated with inferior OS (p = 0.048). Our findings suggest that the TP53 and ATM genes could be involved in the molecular pathophysiology of primary DLBCL CNS, whereas mutations in the PTEN and SMO genes could affect survival regardless of the initial treatment approach.",
publisher = "MDPI, Basel",
journal = "International Journal of Molecular Sciences",
title = "Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses",
number = "5",
volume = "17",
doi = "10.3390/ijms17050683"
}

Todorovic-Balint, M., Jelicić, J., Mihaljević, B., Kostić, J., Stanić, B., Balint, B., Pejanović, N., Lucić, B., Tošić, N., Marjanović, I., Stojiljković, M., Karan-Đurašević, T., Perisić, O., Rakocević, G., Popović, M., Raicević, S., Bila, J., Antić, D., Anđelić, B.,& Pavlović, S.. (2016). Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. in International Journal of Molecular Sciences
MDPI, Basel., 17(5).
https://doi.org/10.3390/ijms17050683

Todorovic-Balint M, Jelicić J, Mihaljević B, Kostić J, Stanić B, Balint B, Pejanović N, Lucić B, Tošić N, Marjanović I, Stojiljković M, Karan-Đurašević T, Perisić O, Rakocević G, Popović M, Raicević S, Bila J, Antić D, Anđelić B, Pavlović S. Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. in International Journal of Molecular Sciences. 2016;17(5).
doi:10.3390/ijms17050683 .

Todorovic-Balint, Milena, Jelicić, Jelena, Mihaljević, Biljana, Kostić, Jelena, Stanić, Bojana, Balint, Bela, Pejanović, Nadja, Lucić, Bojana, Tošić, Nataša, Marjanović, Irena, Stojiljković, Maja, Karan-Đurašević, Teodora, Perisić, Ognjen, Rakocević, Goran, Popović, Milos, Raicević, Sava, Bila, Jelena, Antić, Darko, Anđelić, Boško, Pavlović, Sonja, "Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses" in International Journal of Molecular Sciences, 17, no. 5 (2016),
https://doi.org/10.3390/ijms17050683 . .

TY  - CONF
AU  - Bila, J.
AU  - Sretenović, A.
AU  - Jelicić, J.
AU  - Tošić, Nataša
AU  - Glumac, Irena
AU  - Fekete, M. Dencic
AU  - Antić, Darko
AU  - Todorovic-Balint, Milena
AU  - Marković, O.
AU  - Purić, M.
AU  - Milojević, Z.
AU  - Radojković, M.
AU  - Trajković, G.
AU  - Pavlović, Sonja
AU  - Mihaljević, B.
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/912
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Is there a prognostic impact of the cereblon expression in multiple myeloma?
EP  - 260
SP  - 259
VL  - 101
UR  - https://hdl.handle.net/21.15107/rcub_imagine_912
ER  - 

@conference{
author = "Bila, J. and Sretenović, A. and Jelicić, J. and Tošić, Nataša and Glumac, Irena and Fekete, M. Dencic and Antić, Darko and Todorovic-Balint, Milena and Marković, O. and Purić, M. and Milojević, Z. and Radojković, M. and Trajković, G. and Pavlović, Sonja and Mihaljević, B.",
year = "2016",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Is there a prognostic impact of the cereblon expression in multiple myeloma?",
pages = "260-259",
volume = "101",
url = "https://hdl.handle.net/21.15107/rcub_imagine_912"
}

Bila, J., Sretenović, A., Jelicić, J., Tošić, N., Glumac, I., Fekete, M. D., Antić, D., Todorovic-Balint, M., Marković, O., Purić, M., Milojević, Z., Radojković, M., Trajković, G., Pavlović, S.,& Mihaljević, B.. (2016). Is there a prognostic impact of the cereblon expression in multiple myeloma?. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 101, 259-260.
https://hdl.handle.net/21.15107/rcub_imagine_912

Bila J, Sretenović A, Jelicić J, Tošić N, Glumac I, Fekete MD, Antić D, Todorovic-Balint M, Marković O, Purić M, Milojević Z, Radojković M, Trajković G, Pavlović S, Mihaljević B. Is there a prognostic impact of the cereblon expression in multiple myeloma?. in Haematologica-The Hematology Journal. 2016;101:259-260.
https://hdl.handle.net/21.15107/rcub_imagine_912 .

Bila, J., Sretenović, A., Jelicić, J., Tošić, Nataša, Glumac, Irena, Fekete, M. Dencic, Antić, Darko, Todorovic-Balint, Milena, Marković, O., Purić, M., Milojević, Z., Radojković, M., Trajković, G., Pavlović, Sonja, Mihaljević, B., "Is there a prognostic impact of the cereblon expression in multiple myeloma?" in Haematologica-The Hematology Journal, 101 (2016):259-260,
https://hdl.handle.net/21.15107/rcub_imagine_912 .

TY  - JOUR
AU  - Bila, Jelena
AU  - Sretenović, Aleksandra
AU  - Jelicić, Jelena
AU  - Tošić, Nataša
AU  - Marjanović, Irena
AU  - Fekete, Marija Dencic
AU  - Antić, Darko
AU  - Todorovic-Balint, Milena
AU  - Marković, Olivera
AU  - Milojević, Zoran
AU  - Radojković, Milica
AU  - Trajković, Goran
AU  - Purić, Mila
AU  - Pavlović, Sonja
AU  - Mihaljević, Biljana
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/962
AB  - Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.
PB  - CIG Media Group, Lp, Dallas
T2  - Clinical Lymphoma Myeloma & Leukemia
T1  - Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
EP  - 615
IS  - 11
SP  - 610
VL  - 16
DO  - 10.1016/j.clml.2016.08.007
ER  - 

@article{
author = "Bila, Jelena and Sretenović, Aleksandra and Jelicić, Jelena and Tošić, Nataša and Marjanović, Irena and Fekete, Marija Dencic and Antić, Darko and Todorovic-Balint, Milena and Marković, Olivera and Milojević, Zoran and Radojković, Milica and Trajković, Goran and Purić, Mila and Pavlović, Sonja and Mihaljević, Biljana",
year = "2016",
abstract = "Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.",
publisher = "CIG Media Group, Lp, Dallas",
journal = "Clinical Lymphoma Myeloma & Leukemia",
title = "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma",
pages = "615-610",
number = "11",
volume = "16",
doi = "10.1016/j.clml.2016.08.007"
}

Bila, J., Sretenović, A., Jelicić, J., Tošić, N., Marjanović, I., Fekete, M. D., Antić, D., Todorovic-Balint, M., Marković, O., Milojević, Z., Radojković, M., Trajković, G., Purić, M., Pavlović, S.,& Mihaljević, B.. (2016). Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia
CIG Media Group, Lp, Dallas., 16(11), 610-615.
https://doi.org/10.1016/j.clml.2016.08.007

Bila J, Sretenović A, Jelicić J, Tošić N, Marjanović I, Fekete MD, Antić D, Todorovic-Balint M, Marković O, Milojević Z, Radojković M, Trajković G, Purić M, Pavlović S, Mihaljević B. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia. 2016;16(11):610-615.
doi:10.1016/j.clml.2016.08.007 .

Bila, Jelena, Sretenović, Aleksandra, Jelicić, Jelena, Tošić, Nataša, Marjanović, Irena, Fekete, Marija Dencic, Antić, Darko, Todorovic-Balint, Milena, Marković, Olivera, Milojević, Zoran, Radojković, Milica, Trajković, Goran, Purić, Mila, Pavlović, Sonja, Mihaljević, Biljana, "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma" in Clinical Lymphoma Myeloma & Leukemia, 16, no. 11 (2016):610-615,
https://doi.org/10.1016/j.clml.2016.08.007 . .

TY  - CONF
AU  - Xochelli, Aliki
AU  - Baliakas, Panagiotis
AU  - Agathangelidis, Andreas
AU  - Hadzidimitriou, Anastasia
AU  - Sutton, Lesley-Ann
AU  - Minga, Eva
AU  - Tausch, Eugen
AU  - Yan, Xiao J.
AU  - Shanafelt, Tait D.
AU  - Plevova, Karla
AU  - Boudjogra, Myriam
AU  - Rossi, Davide
AU  - Davis, Zadie
AU  - Navarro, Alba
AU  - Sandberg, Yorick
AU  - Vojdeman, Fie Juhl
AU  - Scarfo, Lydia
AU  - Stavroyianni, Niki
AU  - Sudarikov, Andrey B.
AU  - Veronese, Silvio
AU  - Tzenou, Tatiana
AU  - Karan-Đurašević, Teodora
AU  - Catherwood, Mark
AU  - Kienle, Dirk
AU  - Chatzouli, Maria
AU  - Facco, Monica
AU  - Bahlo, Jasmin
AU  - Pedersen, Lone Bredo
AU  - Mansouri, Larry
AU  - Smedby, Karin E.
AU  - Chu, Charles C.
AU  - Giudicelli, Veronique
AU  - Lefranc, Marie-Paule
AU  - Panagiotidis, Panagiotis
AU  - Juliusson, Gunnar
AU  - Anagnostopoulos, Achilles
AU  - Antić, Darko
AU  - Trentin, Livio
AU  - Montillo, Marco
AU  - Niemann, Carsten
AU  - Dohner, Hartmut
AU  - Langerak, Anton W.
AU  - Darzentas, Nikos
AU  - Pospisilova, Sarka
AU  - Hallek, Michael
AU  - Campo, Elias
AU  - Chiorazzi, Nicholas
AU  - Oscier, David
AU  - Gaidano, Gianluca
AU  - Belessi, Chrysoula
AU  - Jelinek, Diane F.
AU  - Stilgenbauer, Stephan
AU  - Davi, Frederic
AU  - Rosenquist, Richard
AU  - Ghia, Paolo
AU  - Stamatopoulos, Kostas
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/793
PB  - Amer Soc Hematology, Washington
C3  - Blood
T1  - CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference
IS  - 23
VL  - 126
UR  - https://hdl.handle.net/21.15107/rcub_imagine_793
ER  - 

@conference{
author = "Xochelli, Aliki and Baliakas, Panagiotis and Agathangelidis, Andreas and Hadzidimitriou, Anastasia and Sutton, Lesley-Ann and Minga, Eva and Tausch, Eugen and Yan, Xiao J. and Shanafelt, Tait D. and Plevova, Karla and Boudjogra, Myriam and Rossi, Davide and Davis, Zadie and Navarro, Alba and Sandberg, Yorick and Vojdeman, Fie Juhl and Scarfo, Lydia and Stavroyianni, Niki and Sudarikov, Andrey B. and Veronese, Silvio and Tzenou, Tatiana and Karan-Đurašević, Teodora and Catherwood, Mark and Kienle, Dirk and Chatzouli, Maria and Facco, Monica and Bahlo, Jasmin and Pedersen, Lone Bredo and Mansouri, Larry and Smedby, Karin E. and Chu, Charles C. and Giudicelli, Veronique and Lefranc, Marie-Paule and Panagiotidis, Panagiotis and Juliusson, Gunnar and Anagnostopoulos, Achilles and Antić, Darko and Trentin, Livio and Montillo, Marco and Niemann, Carsten and Dohner, Hartmut and Langerak, Anton W. and Darzentas, Nikos and Pospisilova, Sarka and Hallek, Michael and Campo, Elias and Chiorazzi, Nicholas and Oscier, David and Gaidano, Gianluca and Belessi, Chrysoula and Jelinek, Diane F. and Stilgenbauer, Stephan and Davi, Frederic and Rosenquist, Richard and Ghia, Paolo and Stamatopoulos, Kostas",
year = "2015",
publisher = "Amer Soc Hematology, Washington",
journal = "Blood",
title = "CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference",
number = "23",
volume = "126",
url = "https://hdl.handle.net/21.15107/rcub_imagine_793"
}

Xochelli, A., Baliakas, P., Agathangelidis, A., Hadzidimitriou, A., Sutton, L., Minga, E., Tausch, E., Yan, X. J., Shanafelt, T. D., Plevova, K., Boudjogra, M., Rossi, D., Davis, Z., Navarro, A., Sandberg, Y., Vojdeman, F. J., Scarfo, L., Stavroyianni, N., Sudarikov, A. B., Veronese, S., Tzenou, T., Karan-Đurašević, T., Catherwood, M., Kienle, D., Chatzouli, M., Facco, M., Bahlo, J., Pedersen, L. B., Mansouri, L., Smedby, K. E., Chu, C. C., Giudicelli, V., Lefranc, M., Panagiotidis, P., Juliusson, G., Anagnostopoulos, A., Antić, D., Trentin, L., Montillo, M., Niemann, C., Dohner, H., Langerak, A. W., Darzentas, N., Pospisilova, S., Hallek, M., Campo, E., Chiorazzi, N., Oscier, D., Gaidano, G., Belessi, C., Jelinek, D. F., Stilgenbauer, S., Davi, F., Rosenquist, R., Ghia, P.,& Stamatopoulos, K.. (2015). CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. in Blood
Amer Soc Hematology, Washington., 126(23).
https://hdl.handle.net/21.15107/rcub_imagine_793

Xochelli A, Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton L, Minga E, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov AB, Veronese S, Tzenou T, Karan-Đurašević T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc M, Panagiotidis P, Juliusson G, Anagnostopoulos A, Antić D, Trentin L, Montillo M, Niemann C, Dohner H, Langerak AW, Darzentas N, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Oscier D, Gaidano G, Belessi C, Jelinek DF, Stilgenbauer S, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. in Blood. 2015;126(23).
https://hdl.handle.net/21.15107/rcub_imagine_793 .

Xochelli, Aliki, Baliakas, Panagiotis, Agathangelidis, Andreas, Hadzidimitriou, Anastasia, Sutton, Lesley-Ann, Minga, Eva, Tausch, Eugen, Yan, Xiao J., Shanafelt, Tait D., Plevova, Karla, Boudjogra, Myriam, Rossi, Davide, Davis, Zadie, Navarro, Alba, Sandberg, Yorick, Vojdeman, Fie Juhl, Scarfo, Lydia, Stavroyianni, Niki, Sudarikov, Andrey B., Veronese, Silvio, Tzenou, Tatiana, Karan-Đurašević, Teodora, Catherwood, Mark, Kienle, Dirk, Chatzouli, Maria, Facco, Monica, Bahlo, Jasmin, Pedersen, Lone Bredo, Mansouri, Larry, Smedby, Karin E., Chu, Charles C., Giudicelli, Veronique, Lefranc, Marie-Paule, Panagiotidis, Panagiotis, Juliusson, Gunnar, Anagnostopoulos, Achilles, Antić, Darko, Trentin, Livio, Montillo, Marco, Niemann, Carsten, Dohner, Hartmut, Langerak, Anton W., Darzentas, Nikos, Pospisilova, Sarka, Hallek, Michael, Campo, Elias, Chiorazzi, Nicholas, Oscier, David, Gaidano, Gianluca, Belessi, Chrysoula, Jelinek, Diane F., Stilgenbauer, Stephan, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, "CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference" in Blood, 126, no. 23 (2015),
https://hdl.handle.net/21.15107/rcub_imagine_793 .

TY  - CONF
AU  - Elezović, Ivo
AU  - Antić, Darko
AU  - Miljić, Predrag
AU  - Mitrović, Mirjana
AU  - Đorđević, Valentina
AU  - Stojanović, Ljudmila
AU  - Marković, Olivera
AU  - Kovač, Mirjana
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/592
PB  - Pergamon-Elsevier Science Ltd, Oxford
C3  - Thrombosis Research
T1  - Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery
EP  - S133
SP  - S133
VL  - 130
DO  - 10.1016/j.thromres.2012.08.084
ER  - 

@conference{
author = "Elezović, Ivo and Antić, Darko and Miljić, Predrag and Mitrović, Mirjana and Đorđević, Valentina and Stojanović, Ljudmila and Marković, Olivera and Kovač, Mirjana",
year = "2012",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery",
pages = "S133-S133",
volume = "130",
doi = "10.1016/j.thromres.2012.08.084"
}

Elezović, I., Antić, D., Miljić, P., Mitrović, M., Đorđević, V., Stojanović, L., Marković, O.,& Kovač, M.. (2012). Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 130, S133-S133.
https://doi.org/10.1016/j.thromres.2012.08.084

Elezović I, Antić D, Miljić P, Mitrović M, Đorđević V, Stojanović L, Marković O, Kovač M. Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery. in Thrombosis Research. 2012;130:S133-S133.
doi:10.1016/j.thromres.2012.08.084 .

Elezović, Ivo, Antić, Darko, Miljić, Predrag, Mitrović, Mirjana, Đorđević, Valentina, Stojanović, Ljudmila, Marković, Olivera, Kovač, Mirjana, "Clinical manifestation in hereditary thrombophilias and managenemt of thrombosis, pregnancy and delivery" in Thrombosis Research, 130 (2012):S133-S133,
https://doi.org/10.1016/j.thromres.2012.08.084 . .

TY  - JOUR
AU  - Karan-Đurašević, Teodora
AU  - Palibrk, Vuk
AU  - Kostić, Tatjana
AU  - Spasovski, Vesna
AU  - Nikčević, Gordana
AU  - Srzentić Dražilov, Sanja
AU  - Colović, Milica
AU  - Čolović, Nataša
AU  - Vidović, Ana
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/565
AB  - The mutational status and configuration of immunoglobulin heavy variable (IGHV) gene rearrangements was analyzed in 85 Serbian patients with chronic lymphocytic leukemia (CLL). We found that 55.3% of cases belonged to mutated and 44.7% to unmutated CLL, progressive disease predominating in the unmutated subset. IGHV gene use resembled that obtained for Mediterranean countries, except for underrepresentation of the IGHV4 subgroup in our cohort. Background: Chronic lymphocytic leukemia (CLL) results from the clonal expansion of mature B lymphocytes and is characterized by extreme clinical heterogeneity. One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. Biased IGHV gene use between M-CLL and U-CLL clones, as well as population differences in the IGHV gene repertoire have been reported. Patients and Methods: In this study, mutational status and configuration of IGHV-IGHD-IGHJ rearrangements in 85 Serbian patients were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing methodology. Results: We found that 55.3% of cases belonged to M-CLL and 44.7% belonged to U-CLL, with progressive disease predominating in the unmutated subset. Most frequently expressed was the IGHV3 subgroup (55.7%), followed by IGHV1 (27.3%), IGHV4 (12.5%), IGHV5 (2.3%), IGHV2 (1.1%), and IGHV6 (1.1%). The distribution of IGHD subgroups was as follows: IGHD3, 39.1%; IGHD2, 21.8%; IGHD6, 12.6%; IGHD1, 10.3%; IGHD4, 8%; IGHD5, 6.9%; and IGHD7, 1.1%. The most frequent IGHJ gene was IGHJ4 (48.9%), followed by IGHJ6 (28.4%), IGHJ3 (11.4%), and IGHJ5 (11.4%). In 15.3% of cases, heavy complementarity-determining region 3 (VH CDR3) amino acid sequences could be assigned to previously defined stereotyped clusters. Conclusions: Our study showed a strong correlation between IGHV gene mutational status and clinical course of CLL. IGHV gene use was comparable to that obtained for Mediterranean countries, with the exception of the IGHV4 subgroup, which was underrepresented in our cohort. Clinical Lymphoma, Myeloma & Leukemia, Vol. 12, No. 4, 252-60
PB  - CIG Media Group, Lp, Dallas
T2  - Clinical Lymphoma Myeloma & Leukemia
T1  - Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia
EP  - 260
IS  - 4
SP  - 252
VL  - 12
DO  - 10.1016/j.clml.2012.03.005
ER  - 

@article{
author = "Karan-Đurašević, Teodora and Palibrk, Vuk and Kostić, Tatjana and Spasovski, Vesna and Nikčević, Gordana and Srzentić Dražilov, Sanja and Colović, Milica and Čolović, Nataša and Vidović, Ana and Antić, Darko and Mihaljević, Biljana and Pavlović, Sonja and Tošić, Nataša",
year = "2012",
abstract = "The mutational status and configuration of immunoglobulin heavy variable (IGHV) gene rearrangements was analyzed in 85 Serbian patients with chronic lymphocytic leukemia (CLL). We found that 55.3% of cases belonged to mutated and 44.7% to unmutated CLL, progressive disease predominating in the unmutated subset. IGHV gene use resembled that obtained for Mediterranean countries, except for underrepresentation of the IGHV4 subgroup in our cohort. Background: Chronic lymphocytic leukemia (CLL) results from the clonal expansion of mature B lymphocytes and is characterized by extreme clinical heterogeneity. One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses. Biased IGHV gene use between M-CLL and U-CLL clones, as well as population differences in the IGHV gene repertoire have been reported. Patients and Methods: In this study, mutational status and configuration of IGHV-IGHD-IGHJ rearrangements in 85 Serbian patients were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing methodology. Results: We found that 55.3% of cases belonged to M-CLL and 44.7% belonged to U-CLL, with progressive disease predominating in the unmutated subset. Most frequently expressed was the IGHV3 subgroup (55.7%), followed by IGHV1 (27.3%), IGHV4 (12.5%), IGHV5 (2.3%), IGHV2 (1.1%), and IGHV6 (1.1%). The distribution of IGHD subgroups was as follows: IGHD3, 39.1%; IGHD2, 21.8%; IGHD6, 12.6%; IGHD1, 10.3%; IGHD4, 8%; IGHD5, 6.9%; and IGHD7, 1.1%. The most frequent IGHJ gene was IGHJ4 (48.9%), followed by IGHJ6 (28.4%), IGHJ3 (11.4%), and IGHJ5 (11.4%). In 15.3% of cases, heavy complementarity-determining region 3 (VH CDR3) amino acid sequences could be assigned to previously defined stereotyped clusters. Conclusions: Our study showed a strong correlation between IGHV gene mutational status and clinical course of CLL. IGHV gene use was comparable to that obtained for Mediterranean countries, with the exception of the IGHV4 subgroup, which was underrepresented in our cohort. Clinical Lymphoma, Myeloma & Leukemia, Vol. 12, No. 4, 252-60",
publisher = "CIG Media Group, Lp, Dallas",
journal = "Clinical Lymphoma Myeloma & Leukemia",
title = "Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia",
pages = "260-252",
number = "4",
volume = "12",
doi = "10.1016/j.clml.2012.03.005"
}

Karan-Đurašević, T., Palibrk, V., Kostić, T., Spasovski, V., Nikčević, G., Srzentić Dražilov, S., Colović, M., Čolović, N., Vidović, A., Antić, D., Mihaljević, B., Pavlović, S.,& Tošić, N.. (2012). Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia. in Clinical Lymphoma Myeloma & Leukemia
CIG Media Group, Lp, Dallas., 12(4), 252-260.
https://doi.org/10.1016/j.clml.2012.03.005

Karan-Đurašević T, Palibrk V, Kostić T, Spasovski V, Nikčević G, Srzentić Dražilov S, Colović M, Čolović N, Vidović A, Antić D, Mihaljević B, Pavlović S, Tošić N. Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia. in Clinical Lymphoma Myeloma & Leukemia. 2012;12(4):252-260.
doi:10.1016/j.clml.2012.03.005 .

Karan-Đurašević, Teodora, Palibrk, Vuk, Kostić, Tatjana, Spasovski, Vesna, Nikčević, Gordana, Srzentić Dražilov, Sanja, Colović, Milica, Čolović, Nataša, Vidović, Ana, Antić, Darko, Mihaljević, Biljana, Pavlović, Sonja, Tošić, Nataša, "Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia" in Clinical Lymphoma Myeloma & Leukemia, 12, no. 4 (2012):252-260,
https://doi.org/10.1016/j.clml.2012.03.005 . .

TY  - CONF
AU  - Karan-Đurašević, Teodora
AU  - Palibrk, V.
AU  - Tošić, Nataša
AU  - Kostić, Tatjana 
AU  - Spasovski, Vesna
AU  - Nikčević, Gordana
AU  - Srzentić Dražilov, Sanja
AU  - Glumac, Irena
AU  - Colović, M.
AU  - Čolović, Nataša
AU  - Antić, Darko
AU  - Mihaljević, B.
AU  - Scorilas, A.
AU  - Kontos, C.
AU  - Pavlović, Sonja
PY  - 2012
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/613
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica-The Hematology Journal
T1  - Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers
EP  - 298
SP  - 298
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_imagine_613
ER  - 

@conference{
author = "Karan-Đurašević, Teodora and Palibrk, V. and Tošić, Nataša and Kostić, Tatjana  and Spasovski, Vesna and Nikčević, Gordana and Srzentić Dražilov, Sanja and Glumac, Irena and Colović, M. and Čolović, Nataša and Antić, Darko and Mihaljević, B. and Scorilas, A. and Kontos, C. and Pavlović, Sonja",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica-The Hematology Journal",
title = "Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers",
pages = "298-298",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_imagine_613"
}

Karan-Đurašević, T., Palibrk, V., Tošić, N., Kostić, T., Spasovski, V., Nikčević, G., Srzentić Dražilov, S., Glumac, I., Colović, M., Čolović, N., Antić, D., Mihaljević, B., Scorilas, A., Kontos, C.,& Pavlović, S.. (2012). Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers. in Haematologica-The Hematology Journal
Ferrata Storti Foundation, Pavia., 97, 298-298.
https://hdl.handle.net/21.15107/rcub_imagine_613

Karan-Đurašević T, Palibrk V, Tošić N, Kostić T, Spasovski V, Nikčević G, Srzentić Dražilov S, Glumac I, Colović M, Čolović N, Antić D, Mihaljević B, Scorilas A, Kontos C, Pavlović S. Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers. in Haematologica-The Hematology Journal. 2012;97:298-298.
https://hdl.handle.net/21.15107/rcub_imagine_613 .

Karan-Đurašević, Teodora, Palibrk, V., Tošić, Nataša, Kostić, Tatjana , Spasovski, Vesna, Nikčević, Gordana, Srzentić Dražilov, Sanja, Glumac, Irena, Colović, M., Čolović, Nataša, Antić, Darko, Mihaljević, B., Scorilas, A., Kontos, C., Pavlović, Sonja, "Expression of bcl2l12 gene in chronic lymphocytic leukemia: association with clinical and molecular prognostic markers" in Haematologica-The Hematology Journal, 97 (2012):298-298,
https://hdl.handle.net/21.15107/rcub_imagine_613 .

TY  - JOUR
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Cokić, Vladan
AU  - Fekete, Marija Dencic
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Milić, Nataša
AU  - Elezović, Ivo
PY  - 2011
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/518
AB  - We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p  lt  0.0001).
PB  - Taylor & Francis Ltd, Abingdon
T2  - Leukemia & Lymphoma
T1  - Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling
EP  - 1397
IS  - 7
SP  - 1394
VL  - 52
DO  - 10.3109/10428194.2011.578311
ER  - 

@article{
author = "Antić, Darko and Mihaljević, Biljana and Cokić, Vladan and Fekete, Marija Dencic and Karan-Đurašević, Teodora and Pavlović, Sonja and Milić, Nataša and Elezović, Ivo",
year = "2011",
abstract = "We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p  lt  0.0001).",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Leukemia & Lymphoma",
title = "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling",
pages = "1397-1394",
number = "7",
volume = "52",
doi = "10.3109/10428194.2011.578311"
}

Antić, D., Mihaljević, B., Cokić, V., Fekete, M. D., Karan-Đurašević, T., Pavlović, S., Milić, N.,& Elezović, I.. (2011). Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma
Taylor & Francis Ltd, Abingdon., 52(7), 1394-1397.
https://doi.org/10.3109/10428194.2011.578311

Antić D, Mihaljević B, Cokić V, Fekete MD, Karan-Đurašević T, Pavlović S, Milić N, Elezović I. Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma. 2011;52(7):1394-1397.
doi:10.3109/10428194.2011.578311 .

Antić, Darko, Mihaljević, Biljana, Cokić, Vladan, Fekete, Marija Dencic, Karan-Đurašević, Teodora, Pavlović, Sonja, Milić, Nataša, Elezović, Ivo, "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling" in Leukemia & Lymphoma, 52, no. 7 (2011):1394-1397,
https://doi.org/10.3109/10428194.2011.578311 . .

TY  - CONF
AU  - Antić, Darko
AU  - Mihaljević, B.
AU  - Cokić, V.
AU  - Fekete, M. Dencic
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Milić, N.
AU  - Elezović, I.
PY  - 2011
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/516
PB  - Elsevier, Amsterdam
C3  - Annals of Oncology
T1  - Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients
EP  - 242
SP  - 242
VL  - 22
UR  - https://hdl.handle.net/21.15107/rcub_imagine_516
ER  - 

@conference{
author = "Antić, Darko and Mihaljević, B. and Cokić, V. and Fekete, M. Dencic and Karan-Đurašević, Teodora and Pavlović, Sonja and Milić, N. and Elezović, I.",
year = "2011",
publisher = "Elsevier, Amsterdam",
journal = "Annals of Oncology",
title = "Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients",
pages = "242-242",
volume = "22",
url = "https://hdl.handle.net/21.15107/rcub_imagine_516"
}

Antić, D., Mihaljević, B., Cokić, V., Fekete, M. D., Karan-Đurašević, T., Pavlović, S., Milić, N.,& Elezović, I.. (2011). Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients. in Annals of Oncology
Elsevier, Amsterdam., 22, 242-242.
https://hdl.handle.net/21.15107/rcub_imagine_516

Antić D, Mihaljević B, Cokić V, Fekete MD, Karan-Đurašević T, Pavlović S, Milić N, Elezović I. Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients. in Annals of Oncology. 2011;22:242-242.
https://hdl.handle.net/21.15107/rcub_imagine_516 .

Antić, Darko, Mihaljević, B., Cokić, V., Fekete, M. Dencic, Karan-Đurašević, Teodora, Pavlović, Sonja, Milić, N., Elezović, I., "Significance of new prognostic markers in early stage chronic lymphocytic leukemia patients" in Annals of Oncology, 22 (2011):242-242,
https://hdl.handle.net/21.15107/rcub_imagine_516 .